ALPHASUITEATLASTM
NLRP1 · Q9C000Homo sapiens
PROTEIN OVERVIEW

NLRP1NACHT, LRR and PYD domains-containing protein 1

Q9C000Homo sapiensReviewed · UniProt

Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis.

Sequence1473 aa
Source mass165.87 kDa
Recorded PDB entries12
Isoforms listed5

UniProt locations Cytoplasm, cytosol · Cytoplasm · Nucleus · Inflammasome

01

Function

Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis [12, 18, 10, 47, 49, 50, 35, 37, 42, 39]. Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation [12, 18, 10]. Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as cleavage by some human enteroviruses and rhinoviruses, double-stranded RNA, UV-B irradiation, or Val-boroPro inhibitor, and mediates the formation of the inflammasome polymeric complex composed of NLRP1, CASP1 and PYCARD/ASC [12, 18, 10, 27, 30, 29, 50, 33, 35, 39].

In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and associates with PYCARD/ASC to initiate the formation of the inflammasome complex: the NLRP1 inflammasome recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis [12, 18, 10, 32, 50]. In the absence of GSDMD expression, the NLRP1 inflammasome is able to recruit and activate CASP8, leading to activation of gasdermin-E (GSDME) [34, 36]. Activation of NLRP1 inflammasome is also required for HMGB1 secretion; the active cytokines and HMGB1 stimulate inflammatory responses [23].

Binds ATP and shows ATPase activity [4, 14, 33]. Plays an important role in antiviral immunity and inflammation in the human airway epithelium [50]. Specifically recognizes a number of pathogen-associated signals: upon infection by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), NLRP1 is cleaved and activated which triggers NLRP1-dependent inflammasome activation and IL18 secretion [50].

Positive-strand RNA viruses, such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome, triggering IL1B release in a NLRP1-dependent fashion [33]. Acts as a direct sensor for long dsRNA and thus RNA virus infection [33]. May also be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner [19].

The NLRP1 inflammasome is also activated in response to UV-B irradiation causing ribosome collisions: ribosome collisions cause phosphorylation and activation of NLRP1 in a MAP3K20-dependent manner, leading to pyroptosis [39]

Experimental evidence 21 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11113115"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12191486"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15212762"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17349957"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18511561"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22801494"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "25562666"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27662089"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "30096351"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "30291141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "31484767"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "32051255"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33410748"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731929"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731932"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33852854"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35594856"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35857590"
        }
      ],
      "value": "Acts as the sensor component of the NLRP1 inflammasome, which mediates inflammasome activation in response to various pathogen-associated signals, leading to subsequent pyroptosis (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:27662089, PubMed:31484767, PubMed:33093214, PubMed:33410748, PubMed:33731929, PubMed:33731932, PubMed:35857590). Inflammasomes are supramolecular complexes that assemble in the cytosol in response to pathogens and other damage-associated signals and play critical roles in innate immunity and inflammation (PubMed:12191486, PubMed:17349957, PubMed:22665479). Acts as a recognition receptor (PRR): recognizes specific pathogens and other damage-associated signals, such as cleavage by some human enteroviruses and rhinoviruses, double-stranded RNA, UV-B irradiation, or Val-boroPro inhibitor, and mediates the formation of the inflammasome polymeric complex composed of NLRP1, CASP1 and PYCARD/ASC (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:25562666, PubMed:30096351, PubMed:30291141, PubMed:33093214, PubMed:33243852, PubMed:33410748, PubMed:35857590). In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and associates with PYCARD/ASC to initiate the formation of the inflammasome complex: the NLRP1 inflammasome recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, which subsequently cleaves and activates inflammatory cytokines IL1B and IL18 and gasdermin-D (GSDMD), leading to pyroptosis (PubMed:12191486, PubMed:17349957, PubMed:22665479, PubMed:32051255, PubMed:33093214). In the absence of GSDMD expression, the NLRP1 inflammasome is able to recruit and activate CASP8, leading to activation of gasdermin-E (GSDME) (PubMed:33852854, PubMed:35594856). Activation of NLRP1 inflammasome is also required for HMGB1 secretion; the active cytokines and HMGB1 stimulate inflammatory responses (PubMed:22801494). Binds ATP and shows ATPase activity (PubMed:11113115, PubMed:15212762, PubMed:33243852). Plays an important role in antiviral immunity and inflammation in the human airway epithelium (PubMed:33093214). Specifically recognizes a number of pathogen-associated signals: upon infection by human rhinoviruses 14 and 16 (HRV-14 and HRV-16), NLRP1 is cleaved and activated which triggers NLRP1-dependent inflammasome activation and IL18 secretion (PubMed:33093214). Positive-strand RNA viruses, such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome, triggering IL1B release in a NLRP1-dependent fashion (PubMed:33243852). Acts as a direct sensor for long dsRNA and thus RNA virus infection (PubMed:33243852). May also be activated by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, in a NOD2-dependent manner (PubMed:18511561). The NLRP1 inflammasome is also activated in response to UV-B irradiation causing ribosome collisions: ribosome collisions cause phosphorylation and activation of NLRP1 in a MAP3K20-dependent manner, leading to pyroptosis (PubMed:35857590)"
    }
  ],
  "commentType": "FUNCTION"
}
NACHT, LRR and PYD domains-containing protein 1

Constitutes the precursor of the NLRP1 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22087307"
        }
      ],
      "value": "Constitutes the precursor of the NLRP1 inflammasome, which mediates autoproteolytic processing within the FIIND domain to generate the N-terminal and C-terminal parts, which are associated non-covalently in absence of pathogens and other damage-associated signals"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1"
}
NACHT, LRR and PYD domains-containing protein 1, N-terminus

Regulatory part that prevents formation of the NLRP1 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus), preventing activation of the NLRP1 inflammasome [50]. In response to pathogen-associated signals, this part is ubiquitinated and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the NLRP1 inflammasome [50]

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        }
      ],
      "value": "Regulatory part that prevents formation of the NLRP1 inflammasome: in absence of pathogens and other damage-associated signals, interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214). In response to pathogen-associated signals, this part is ubiquitinated and degraded by the proteasome, releasing the cleaved C-terminal part of the protein, which polymerizes and forms the NLRP1 inflammasome (PubMed:33093214)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}
NACHT, LRR and PYD domains-containing protein 1, C-terminus

Constitutes the active part of the NLRP1 inflammasome [50, 37, 42]. In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus), preventing activation of the NLRP1 inflammasome [50]. In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing this form, which polymerizes and associates with PYCARD/ASC to form of the NLRP1 inflammasome complex: the NLRP1 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis [50]

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731929"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731932"
        }
      ],
      "value": "Constitutes the active part of the NLRP1 inflammasome (PubMed:33093214, PubMed:33731929, PubMed:33731932). In absence of pathogens and other damage-associated signals, interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus), preventing activation of the NLRP1 inflammasome (PubMed:33093214). In response to pathogen-associated signals, the N-terminal part of NLRP1 is degraded by the proteasome, releasing this form, which polymerizes and associates with PYCARD/ASC to form of the NLRP1 inflammasome complex: the NLRP1 inflammasome complex then directly recruits pro-caspase-1 (proCASP1) and promotes caspase-1 (CASP1) activation, leading to gasdermin-D (GSDMD) cleavage and subsequent pyroptosis (PubMed:33093214)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}
Isoform 2

It is unclear whether is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release [10]. However, in an vitro cell-free system, it has been shown to be activated by MDP [18]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17349957"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        }
      ],
      "value": "It is unclear whether is involved in inflammasome formation. It is not cleaved within the FIIND domain, does not assemble into specks, nor promote IL1B release (PubMed:22665479). However, in an vitro cell-free system, it has been shown to be activated by MDP (PubMed:17349957)"
    }
  ],
  "commentType": "FUNCTION",
  "molecule": "Isoform 2"
}

Additional functional context

In macrophages and dendritic cells, NLRP1 inflammasome activation of CASP1 and IL1B maturation can be dampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, such as CD40LG

By similarity
Evidence & references
  • ECO:0000250 UniProtKB:Q2LKW6
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q2LKW6"
        }
      ],
      "value": "In macrophages and dendritic cells, NLRP1 inflammasome activation of CASP1 and IL1B maturation can be dampened by direct contact with activated effector and memory T-cells. This effect may be mediated by hexameric TNF ligands, such as CD40LG"
    }
  ],
  "commentType": "MISCELLANEOUS"
}

Catalytic activity

ATP + H2O = ADP + phosphate + H(+)

Evidence
Complete source annotation
{
  "commentType": "CATALYTIC ACTIVITY",
  "reaction": {
    "name": "ATP + H2O = ADP + phosphate + H(+)",
    "reactionCrossReferences": [
      {
        "database": "Rhea",
        "id": "RHEA:13065"
      },
      {
        "database": "ChEBI",
        "id": "CHEBI:15377"
      },
      {
        "database": "ChEBI",
        "id": "CHEBI:15378"
      },
      {
        "database": "ChEBI",
        "id": "CHEBI:30616"
      },
      {
        "database": "ChEBI",
        "id": "CHEBI:43474"
      },
      {
        "database": "ChEBI",
        "id": "CHEBI:456216"
      }
    ],
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "33243852"
      }
    ]
  },
  "physiologicalReactions": [
    {
      "directionType": "left-to-right",
      "reactionCrossReference": {
        "database": "Rhea",
        "id": "RHEA:13066"
      },
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        }
      ]
    }
  ]
}

Activity regulation

NLRP1 inflammasome is activated by cleavage by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16): cleavage promotes ubiquitination and degradation of the N-terminal part, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome [50, 35]. Activated double-stranded RNA: positive-strand RNA viruses such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome [33]. In contrast to its mouse ortholog, not activated by Bacillus anthracis lethal toxin [21].

NLRP1 inflammasome is inhibited by DPP8 and DPP9, which sequester the C-terminal fragment of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in a ternary complex, thereby preventing NLRP1 oligomerization and activation [29, 31, 37, 42]. NLRP1 inflammasome is activated by Val-boroPro (Talabostat, PT-100), an inhibitor of dipeptidyl peptidases DPP8 and DPP9 [29, 37, 42]. Val-boroPro relieves inhibition of DPP8 and/or DPP9 by promoting disruption of the ternary complex, releasing its C-terminal part from autoinhibition [37, 42].

ATPase activity is activated by dsRNA-binding but not dsDNA-binding [33]

Experimental evidence 8 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "19651869"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "30291141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "31525884"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33410748"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731929"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731932"
        }
      ],
      "value": "NLRP1 inflammasome is activated by cleavage by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16): cleavage promotes ubiquitination and degradation of the N-terminal part, releasing the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome (PubMed:33093214, PubMed:33410748). Activated double-stranded RNA: positive-strand RNA viruses such as Semliki forest virus and long dsRNA activate the NLRP1 inflammasome (PubMed:33243852). In contrast to its mouse ortholog, not activated by Bacillus anthracis lethal toxin (PubMed:19651869). NLRP1 inflammasome is inhibited by DPP8 and DPP9, which sequester the C-terminal fragment of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in a ternary complex, thereby preventing NLRP1 oligomerization and activation (PubMed:30291141, PubMed:31525884, PubMed:33731929, PubMed:33731932). NLRP1 inflammasome is activated by Val-boroPro (Talabostat, PT-100), an inhibitor of dipeptidyl peptidases DPP8 and DPP9 (PubMed:30291141, PubMed:33731929, PubMed:33731932). Val-boroPro relieves inhibition of DPP8 and/or DPP9 by promoting disruption of the ternary complex, releasing its C-terminal part from autoinhibition (PubMed:33731929, PubMed:33731932). ATPase activity is activated by dsRNA-binding but not dsDNA-binding (PubMed:33243852)"
    }
  ],
  "commentType": "ACTIVITY REGULATION"
}

(Microbial infection) The NLRP1 inflammasome is activated by human herpes virus 8/HHV-8 protein ORF45, which interacts with the N-terminal part of NLRP1 and promotes its translocation into the nucleus, relieving autoinhibition and leading to activation

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35618833"
        }
      ],
      "value": "(Microbial infection) The NLRP1 inflammasome is activated by human herpes virus 8/HHV-8 protein ORF45, which interacts with the N-terminal part of NLRP1 and promotes its translocation into the nucleus, relieving autoinhibition and leading to activation"
    }
  ],
  "commentType": "ACTIVITY REGULATION"
}

(Microbial infection) NLRP1 inflammasome is activated by cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35594856"
        }
      ],
      "value": "(Microbial infection) NLRP1 inflammasome is activated by cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2"
    }
  ],
  "commentType": "ACTIVITY REGULATION"
}

GO functions & biological processes

double-stranded DNA bindingenablesUniProtKB:Q9C000
GO
GO:0003690 · evidence & context
double-stranded RNA bindingenablesUniProtKB:Q9C000
GO
GO:0003725 · evidence & context
protein bindingenablesUniProtKB:Q9C000
GO
GO:0005515 · evidence & context
  • ECO:0000353 PMID:11472070 ↗ IPI · UniProt · 20061120
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPP4"}]}]
  • ECO:0000353 PMID:15107016 ↗ IPI · HGNC-UCL · 20060524
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
  • ECO:0000353 PMID:15107016 ↗ IPI · HGNC-UCL · 20060524
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9NPP4"}]}]
  • ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10415"}]}]
  • ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
  • ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07817"}]}]
  • ECO:0000353 PMID:17418785 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}]
  • ECO:0000353 PMID:18511561 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P29466"}]}]
  • ECO:0000353 PMID:19223583 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P10415"}]}]
  • ECO:0000353 PMID:19223583 ↗ IPI · IntAct · 20260725
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q07817-1"}]}]
  • ECO:0000353 PMID:19337385 ↗ IPI · BHF-UCL · 20110124
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q9HC29"}]}]
  • ECO:0000353 PMID:22801494 ↗ IPI · UniProt · 20130416
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P19525"}]}]
  • ECO:0000353 PMID:30291141 ↗ IPI · UniProt · 20210503
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86TI2"}]}]
  • ECO:0000353 PMID:33731929 ↗ IPI · UniProt · 20211222
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q86TI2"}]}]
ATP bindingenablesUniProtKB:Q9C000
GO
GO:0005524 · evidence & context
cysteine-type endopeptidase activator activity involved in apoptotic processenablesUniProtKB:Q9C000
GO
GO:0008656 · evidence & context
All recorded function and process assertions (40)
ATP hydrolysis activityenablesUniProtKB:Q9C000
GO
GO:0016887 · evidence & context
enzyme bindingenablesUniProtKB:Q9C000
GO
GO:0019899 · evidence & context
  • ECO:0000353 PMID:11076957 ↗ IPI · UniProt · 20021104
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "P42575"}]}]
protein domain specific bindingenablesUniProtKB:Q9C000
GO
GO:0019904 · evidence & context
  • ECO:0000353 PMID:16575408 ↗ IPI · UniProt · 20090511
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "O95361"}]}]
signaling adaptor activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0035591 · evidence & context
  • ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220125
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q9ULZ3", "relation": "has_input"}, {"db": "GO", "id": "0140608", "relation": "directly_positively_regulates"}]}]
pattern recognition receptor activityenablesUniProtKB:Q9C000
GO
GO:0038187 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
pattern recognition receptor activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0038187 · evidence & context
  • ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20220125
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
cysteine-type endopeptidase activator activityenablesUniProtKB:Q9C000
GO
GO:0140608 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411
    qualifier: enables
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
  • ECO:0000314 PMID:30291141 ↗ IDA · UniProt · 20210504
    qualifier: enables
cysteine-type endopeptidase activator activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140608 · evidence & context
  • ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220811
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "GO", "id": "0005829", "relation": "occurs_in"}, {"db": "UniProtKB", "id": "P29466", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
cysteine-type endopeptidase activator activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140608 · evidence & context
  • ECO:0000314 PMID:22665479 ↗ IDA · UniProt · 20220916
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "P29466", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
cysteine-type endopeptidase activator activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140608 · evidence & context
  • ECO:0000314 PMID:33852854 ↗ IDA · UniProt · 20220916
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}]}]
  • ECO:0000314 PMID:35594856 ↗ IDA · UniProt · 20220916
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}]}]
cysteine-type endopeptidase activator activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140608 · evidence & context
  • ECO:0000314 PMID:33852854 ↗ IDA · UniProt · 20220916
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "UniProtKB", "id": "Q14790", "relation": "has_input"}, {"db": "GO", "id": "0004197", "relation": "directly_positively_regulates"}]}]
molecular condensate scaffold activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140693 · evidence & context
  • ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20220125
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
  • ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20220125
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}]}]
molecular condensate scaffold activityenablesUniProtKB:Q9C000 · Context-qualified assertion; see evidence
GO
GO:0140693 · evidence & context
  • ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20220916
    qualifier: enables
    extensions: [{"connectedXrefs": [{"db": "GO", "id": "1904784", "relation": "part_of"}, {"db": "GO", "id": "0035591", "relation": "directly_positively_regulates"}]}]
activation of innate immune responseinvolved inUniProtKB:Q9C000
GO
GO:0002218 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20250413
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
pattern recognition receptor signaling pathwayinvolved inUniProtKB:Q9C000
GO
GO:0002221 · evidence & context
apoptotic processinvolved inUniProtKB:Q9C000
GO
GO:0006915 · evidence & context
inflammatory responseinvolved inUniProtKB:Q9C000
GO
GO:0006954 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR033516"}]}]
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20241121
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "MGI", "id": "MGI:3582959"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
signal transductioninvolved inUniProtKB:Q9C000
GO
GO:0007165 · evidence & context
response to muramyl dipeptideinvolved inUniProtKB:Q9C000
GO
GO:0032495 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
positive regulation of interleukin-1 beta productioninvolved inUniProtKB:Q9C000
GO
GO:0032731 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00033916"}]}]
  • ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207
    qualifier: involved_in
  • ECO:0000314 PMID:7642516 ↗ IDA · ComplexPortal · 20250804
    qualifier: involved_in
defense response to bacteriuminvolved inUniProtKB:Q9C000
GO
GO:0042742 · evidence & context
  • ECO:0000250 GO_REF:0000024 ISS · BHF-UCL · 20110124
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB", "id": "Q2LKU9"}]}]
regulation of apoptotic processinvolved inUniProtKB:Q9C000
GO
GO:0042981 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR001315"}]}]
innate immune responseinvolved inUniProtKB:Q9C000
GO
GO:0045087 · evidence & context
  • ECO:0000256 GO_REF:0000002 IEA · InterPro · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "InterPro", "id": "IPR033516"}]}]
regulation of inflammatory responseinvolved inUniProtKB:Q9C000
GO
GO:0050727 · evidence & context
positive regulation of inflammatory responseinvolved inUniProtKB:Q9C000
GO
GO:0050729 · evidence & context
protein homooligomerizationinvolved inUniProtKB:Q9C000
GO
GO:0051260 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00089314"}]}]
  • ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20210504
    qualifier: involved_in
  • ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20210504
    qualifier: involved_in
neuron apoptotic processinvolved inUniProtKB:Q9C000
GO
GO:0051402 · evidence & context
defense response to virusinvolved inUniProtKB:Q9C000
GO
GO:0051607 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00026923"}]}]
  • ECO:0000314 PMID:33093214 ↗ IDA · UniProt · 20201030
    qualifier: involved_in
  • ECO:0000314 PMID:33243852 ↗ IDA · UniProt · 20201207
    qualifier: involved_in
pyroptotic inflammatory responseinvolved inUniProtKB:Q9C000
GO
GO:0070269 · evidence & context
cellular response to UV-Binvolved inUniProtKB:Q9C000
GO
GO:0071493 · evidence & context
intrinsic apoptotic signaling pathwayinvolved inUniProtKB:Q9C000
GO
GO:0097193 · evidence & context
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}]
self proteolysisinvolved inUniProtKB:Q9C000
GO
GO:0097264 · evidence & context
antiviral innate immune responseinvolved inUniProtKB:Q9C000
GO
GO:0140374 · evidence & context
canonical inflammasome complex assemblyinvolved inUniProtKB:Q9C000
GO
GO:0140632 · evidence & context
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: involved_in
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00085691"}]}]
NLRP1 inflammasome complex assemblyinvolved inUniProtKB:Q9C000
GO
GO:1904784 · evidence & context
02

Names & Taxonomy

Recommended name
NACHT, LRR and PYD domains-containing protein 1
Gene
NLRP1
Accession / entry
Q9C000 · NLRP1_HUMAN
Species
Homo sapiens · NCBI 9606
Recorded aliases
CARD7 · Caspase recruitment domain-containing protein 7 · DEFCAP · Death effector filament-forming ced-4-like apoptosis protein · KIAA0926 · NAC · NALP1 · Nucleotide-binding domain and caspase recruitment domain
Full taxonomy & recorded names

Eukaryota → Metazoa → Chordata → Craniata → Vertebrata → Euteleostomi → Mammalia → Eutheria → Euarchontoglires → Primates → Haplorrhini → Catarrhini → Hominidae → Homo

{
  "names": {
    "recommendedName": {
      "fullName": {
        "evidences": [
          {
            "evidenceCode": "ECO:0000305"
          }
        ],
        "value": "NACHT, LRR and PYD domains-containing protein 1"
      },
      "ecNumbers": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000269",
              "source": "PubMed",
              "id": "22087307"
            }
          ],
          "value": "3.4.-.-"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000269",
              "source": "PubMed",
              "id": "33243852"
            }
          ],
          "value": "3.6.4.-"
        }
      ]
    },
    "alternativeNames": [
      {
        "fullName": {
          "value": "Caspase recruitment domain-containing protein 7"
        }
      },
      {
        "fullName": {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "Death effector filament-forming ced-4-like apoptosis protein"
        }
      },
      {
        "fullName": {
          "value": "Nucleotide-binding domain and caspase recruitment domain"
        }
      }
    ],
    "contains": [
      {
        "recommendedName": {
          "fullName": {
            "evidences": [
              {
                "evidenceCode": "ECO:0000305"
              }
            ],
            "value": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
          },
          "shortNames": [
            {
              "evidences": [
                {
                  "evidenceCode": "ECO:0000303",
                  "source": "PubMed",
                  "id": "33420033"
                }
              ],
              "value": "NLRP1-CT"
            }
          ]
        }
      },
      {
        "recommendedName": {
          "fullName": {
            "evidences": [
              {
                "evidenceCode": "ECO:0000305"
              }
            ],
            "value": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
          },
          "shortNames": [
            {
              "evidences": [
                {
                  "evidenceCode": "ECO:0000303",
                  "source": "PubMed",
                  "id": "33420033"
                }
              ],
              "value": "NLRP1-NT"
            }
          ]
        }
      }
    ]
  },
  "genes": [
    {
      "geneName": {
        "evidences": [
          {
            "evidenceCode": "ECO:0000303",
            "source": "PubMed",
            "id": "22665479"
          },
          {
            "evidenceCode": "ECO:0000312",
            "source": "HGNC",
            "id": "HGNC:14374"
          }
        ],
        "value": "NLRP1"
      },
      "synonyms": [
        {
          "value": "CARD7"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "DEFCAP"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "10231032"
            }
          ],
          "value": "KIAA0926"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15285719"
            }
          ],
          "value": "NALP1"
        }
      ]
    }
  ]
}
03

Subcellular Location

UniProt locations and GO cellular-component assertions. Relations and contexts remain distinct; “part of” is not automatically a residence claim.

Cytoplasm, cytosolReported location

Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic

UniProt
Experimental evidence 1 publication
Evidence & references
CytoplasmReported location

Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic

UniProt
Experimental evidence 1 publication
Evidence & references
NucleusReported location

Nucleocytoplasmic distribution in lymphoid organs (probably in T-cells) and in neurons. In epithelial cells, predominantly cytoplasmic

UniProt
Experimental evidence 1 publication
Evidence & references
InflammasomeReported location

NACHT, LRR and PYD domains-containing protein 1, C-terminus

UniProt
Experimental evidence 5 publications
Evidence & references
NucleusReported location

NACHT, LRR and PYD domains-containing protein 1, N-terminus

(Microbial infection) Interaction with human herpes virus 8/HHV-8 proteins ORF45 promotes translocation of the N-terminal part of NLRP1 into the nucleus, relieving autoinhibition of the NLRP1 inflammasome and leading to its activation

UniProt
Experimental evidence 1 publication
Evidence & references
nucleusis active in
GO
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20260530
    qualifier: is_active_in
    withFrom: [{"connectedXrefs": [{"db": "MGI", "id": "MGI:1931465"}]}, {"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9C000"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}]
cytosolis active in
GO
2 publications
Evidence & references
nucleuslocated in
GO
Experimental evidence 2 publications
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0191"}]}]
  • ECO:0000314 PMID:17164409 ↗ IDA · BHF-UCL · 20110124
    qualifier: located_in
  • ECO:0000269 PMID:35618833 ↗ EXP · UniProt · 20250406
    qualifier: located_in
All recorded location assertions (15)
nucleoplasmlocated in
GO
Evidence & references
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
nucleoluslocated in
GO
1 publication
Evidence & references
cytoplasmlocated in
GO
Experimental evidence 2 publications
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0086"}]}]
  • ECO:0000269 PMID:17164409 ↗ EXP · UniProt · 20250406
    qualifier: located_in
  • ECO:0005547 PMID:28263976 ↗ NAS · ComplexPortal · 20250804
    qualifier: located_in
cytosollocated in
GO
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: located_in
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0091"}]}]
  • ECO:0000314 GO_REF:0000052 IDA · HPA · 20251115
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-844438 TAS · Reactome · 20130516
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-844447 TAS · Reactome · 20130516
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-879201 TAS · Reactome · 20130516
    qualifier: located_in
  • ECO:0000304 Reactome:R-HSA-879222 TAS · Reactome · 20130516
    qualifier: located_in
canonical inflammasome complexpart of
GO
Experimental evidence 5 publications
Evidence & references
  • ECO:0007322 GO_REF:0000044 IEA · UniProt · 20260727
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "UniProtKB-SubCell", "id": "SL-0488"}]}]
  • ECO:0000269 PMID:12191486 ↗ EXP · UniProt · 20250406
    qualifier: part_of
  • ECO:0000269 PMID:22665479 ↗ EXP · UniProt · 20250406
    qualifier: part_of
  • ECO:0000269 PMID:30291141 ↗ EXP · UniProt · 20250406
    qualifier: part_of
  • ECO:0000269 PMID:33420028 ↗ EXP · UniProt · 20250406
    qualifier: part_of
  • ECO:0000269 PMID:33420033 ↗ EXP · UniProt · 20250406
    qualifier: part_of
NLRP1 inflammasome complexpart of
GO
6 publications
Evidence & references
  • ECO:0000256 GO_REF:0000117 IEA · UniProt · 20260727
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "ARBA", "id": "ARBA00092910"}]}]
  • ECO:0000314 PMID:12191486 ↗ IDA · UniProt · 20121018
    qualifier: part_of
  • ECO:0000353 PMID:17349957 ↗ IPI · ComplexPortal · 20250804
    qualifier: part_of
  • ECO:0000304 PMID:20303873 ↗ TAS · BHF-UCL · 20110223
    qualifier: part_of
  • ECO:0000314 PMID:30291141 ↗ IDA · UniProt · 20210504
    qualifier: part_of
  • ECO:0000314 PMID:33420028 ↗ IDA · UniProt · 20210504
    qualifier: part_of
  • ECO:0000314 PMID:33420033 ↗ IDA · UniProt · 20210504
    qualifier: part_of
NLRP3 inflammasome complexpart of
GO
Evidence & references
  • ECO:0000318 GO_REF:0000033 IBA · GO_Central · 20240411
    qualifier: part_of
    withFrom: [{"connectedXrefs": [{"db": "PANTHER", "id": "PTN005327833"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9ULZ3"}]}, {"connectedXrefs": [{"db": "UniProtKB", "id": "Q9Y2G2"}]}, {"connectedXrefs": [{"db": "ZFIN", "id": "ZDB-GENE-000511-2"}]}]

Membrane topology 0

No annotation is recorded in this UniProt entry.

04

Disease & Variants

Source annotations; a recorded variant is not automatically a clinical classification.

Vitiligo-associated multiple autoimmune disease 1 VAMAS1

A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.

Experimental evidence 1 publication
Evidence & references

Disease susceptibility is associated with variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Vitiligo-associated multiple autoimmune disease 1",
    "diseaseAccession": "DI-02736",
    "acronym": "VAMAS1",
    "description": "A disorder characterized by the association of vitiligo with several autoimmune and autoinflammatory diseases including autoimmune thyroid disease, rheumatoid arthritis and systemic lupus erythematosus.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "606579"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "17377159"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "Disease susceptibility is associated with variants affecting the gene represented in this entry"
      }
    ]
  }
}

Palmoplantar carcinoma, multiple self-healing MSPC

An autosomal dominant disease characterized by keratopathy with neovascularization, bilateral corneal opacification, palmoplantar hyperkeratosis, dyshidrosis, dystrophic nails, and recurrent keratoacanthomas in palmoplantar skin as well as in conjunctival and corneal epithelia. In addition, patients experience a high susceptibility to malignant squamous cell carcinoma.

Experimental evidence 3 publications
Evidence & references

The disease is caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Palmoplantar carcinoma, multiple self-healing",
    "diseaseAccession": "DI-03762",
    "acronym": "MSPC",
    "description": "An autosomal dominant disease characterized by keratopathy with neovascularization, bilateral corneal opacification, palmoplantar hyperkeratosis, dyshidrosis, dystrophic nails, and recurrent keratoacanthomas in palmoplantar skin as well as in conjunctival and corneal epithelia. In addition, patients experience a high susceptibility to malignant squamous cell carcinoma.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "615225"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "23349227"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "27662089"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "33093214"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease is caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Autoinflammation with arthritis and dyskeratosis AIADK

A disorder characterized by recurrent fever, diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Inheritance can be autosomal dominant or autosomal recessive.

Experimental evidence 3 publications
Evidence & references

The disease may be caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Autoinflammation with arthritis and dyskeratosis",
    "diseaseAccession": "DI-04967",
    "acronym": "AIADK",
    "description": "A disorder characterized by recurrent fever, diffuse skin dyskeratosis, autoinflammation, autoimmunity, arthritis and high transitional B-cell level. Inheritance can be autosomal dominant or autosomal recessive.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "617388"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "27965258"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "30291141"
      },
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "33731932"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease may be caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Respiratory papillomatosis, juvenile recurrent, congenital JRRP

An autosomal recessive disease characterized by recurrent growth of papillomas in the respiratory tract, and onset in early childhood. Papillomas are most commonly found in the larynx but may occur anywhere from the mouth to the bronchi. Children typically present within the first years of life with hoarseness or, in more severe cases, respiratory distress or stridor and airway obstruction. JRRP is associated with infection of the upper airway by human papillomaviruses of the alpha genus. The infection is thought to occur by vertical transmission at birth.

Experimental evidence 1 publication
Evidence & references

The disease may be caused by variants affecting the gene represented in this entry

Evidence & references

No separate evidence record is supplied for this statement.

Complete source annotation
{
  "commentType": "DISEASE",
  "disease": {
    "diseaseId": "Respiratory papillomatosis, juvenile recurrent, congenital",
    "diseaseAccession": "DI-05784",
    "acronym": "JRRP",
    "description": "An autosomal recessive disease characterized by recurrent growth of papillomas in the respiratory tract, and onset in early childhood. Papillomas are most commonly found in the larynx but may occur anywhere from the mouth to the bronchi. Children typically present within the first years of life with hoarseness or, in more severe cases, respiratory distress or stridor and airway obstruction. JRRP is associated with infection of the upper airway by human papillomaviruses of the alpha genus. The infection is thought to occur by vertical transmission at birth.",
    "diseaseCrossReference": {
      "database": "MIM",
      "id": "618803"
    },
    "evidences": [
      {
        "evidenceCode": "ECO:0000269",
        "source": "PubMed",
        "id": "31484767"
      }
    ]
  },
  "note": {
    "texts": [
      {
        "value": "The disease may be caused by variants affecting the gene represented in this entry"
      }
    ]
  }
}

Natural variants 17

Scroll across the table for evidence and actions.

17 recorded rows

FeaturePositionDescriptionEvidenceInspect
A54TVAR_07879854in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP:rs1057519492
A → T
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
A66VVAR_07879966in MSPC; increased NLRP1-inflammasome complex assembly; altered protein folding; dbSNP:rs1057519493
A → V
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M77TVAR_06990177in MSPC; destabilization of the N-terminal fragment; dbSNP:rs397514692
M → T
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
L155HVAR_033239155risk factor for VAMAS1; dbSNP:rs12150220
L → H
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
T246SVAR_024238246in dbSNP:rs11651595
T → S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R404QVAR_021886404in dbSNP:rs3744718
R → Q
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
R726WVAR_078800726in AIADK; uncertain significance; dbSNP:rs776245016
R → W
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T755NVAR_083844755in JRRP; gain-of-function variant resulting in spontaneous inflammasome activation; increased NLRP1-inflammasome complex assembly
T → N
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Natural variantVAR_078801787–843in MSPC; increased NLRP1-inflammasome complex assembly
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T878MVAR_033240878in dbSNP:rs11657747
T → M
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
V1059MVAR_0242391059in dbSNP:rs2301582
V → M
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
H1069YVAR_0332411069in dbSNP:rs9907167
H → Y
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
M1119VVAR_0332421119no effect on autocatalytic processing, nor on IL1B release; dbSNP:rs35596958
M → V
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
M1184VVAR_0332431184increased autocatalytic processing and IL1B release; dbSNP:rs11651270
M → V
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
P1214RVAR_0788021214in AIADK; decreased interaction with DPP9, leading to increased inflammasome activity; dbSNP:rs1057524876
P → R
Experimental evidence 3 publications
Evidence & references
No verified residues in this structure
V1241LVAR_0332441241in dbSNP:rs11653832
V → L
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1366CVAR_0204371366in dbSNP:rs2137722
R → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure

Laboratory mutagenesis 69

Scroll across the table for evidence and actions.

69 recorded rows

FeaturePositionDescriptionEvidenceInspect
Q76A76No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q85A85No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q87A87No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q110A110No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q130A130Inhibits cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q130P130Inhibits cleavage by Protease 3C from Coxsackievirus B3 and HRV-14.
Q → P
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q139A139No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q158A158No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q171A171No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
TST178AAA178–180In 3A mutant; abolished activation of the NLRP1 inflammasome in response to UV-B irradiation and ribosome collisions.
TST → AAA
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q191A191No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q199A199No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q205A205No effect on cleavage by HRV-14 Protease 3C.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q333A333Abolished cleavage by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2.
Q → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
GK339EA339–340Loss of ATP binding.
GK → EA
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K340L / K340S340No effect.
K → L, S
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1168A1168Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine.
H → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1186A1186Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing can be restored by treatment with hydroxylamine.
H → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
LL1193EE1193–1194Reduced autocatalytic processing and reduced interaction with DPP9.
LL → EE
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1211A1211Partial loss of autocatalytic processing and of IL1B release.
S → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F1212A1212Complete loss of autocatalytic processing and of IL1B release.
F → A
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
S1213A1213Complete loss of autocatalytic processing and of IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine. Abolished interaction with DPP9. Loss of activation by dsRNA or positive-strand RNA virus.
S → A
Experimental evidence 6 publications
Evidence & references
No verified residues in this structure
S1213C1213Complete loss of autocatalytic processing, which can be restored by treatment with hydroxylamine.
S → C
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P1214A1214Partial loss of autocatalytic processing (50%) and of IL1B release (50%).
P → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1240D1240Slightly reduced formation of an inflammasome filament together with PYCARD/ASC.
R → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1249A1249Complete loss of autocatalytic processing and IL1B release. Autocatalytic processing cannot be restored by treatment with hydroxylamine.
H → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
RK1260DD1260–1261Slightly reduced formation of an inflammasome filament together with PYCARD/ASC.
RK → DD
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1276G1276Abolished ability to form the NLRP1 inflammasome.
H → G
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1277E1277Abolished ability to form the NLRP1 inflammasome.
K → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
PP1278AG1278–1279Abolished formation of an inflammasome filament together with PYCARD/ASC.
PP → AG
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
P1278E1278Impaired ability to form the NLRP1 inflammasome.
P → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
L1281E1281Impaired ability to form the NLRP1 inflammasome.
L → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
F1320A1320Slightly reduced formation of an inflammasome filament together with PYCARD/ASC.
F → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1322R1322Abolished ability to form the NLRP1 inflammasome.
E → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D1383R1383Abolished formation of an inflammasome filament together with PYCARD/ASC.
D → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1386D1386Abolished formation of an inflammasome filament together with PYCARD/ASC.
R → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1387R1387Does not affect formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q1388D1388Does not affect formation of an inflammasome filament together with PYCARD/ASC.
Q → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1392D1392Abolished formation of an inflammasome filament together with PYCARD/ASC.
R → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1392E1392Impaired ability to induce programmed cell death.
R → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
S1395R1395Abolished formation of an inflammasome filament together with PYCARD/ASC.
S → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1397R1397Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
D1401R1401Impaired ability to induce programmed cell death.
D → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1402D1402Abolished formation of an inflammasome filament together with PYCARD/ASC.
K → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1402E1402Abolished formation of an inflammasome filament together with PYCARD/ASC.
K → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1404D1404Abolished formation of an inflammasome filament together with PYCARD/ASC.
H → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q1406R1406Does not affect formation of an inflammasome filament together with PYCARD/ASC.
Q → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q1410R1410Abolished formation of an inflammasome filament together with PYCARD/ASC.
Q → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1411R1411Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Y1413R1413Abolished formation of an inflammasome filament together with PYCARD/ASC.
Y → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1414R1414Impaired ability to induce programmed cell death. Abolished formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
R1415D1415Abolished formation of an inflammasome filament together with PYCARD/ASC.
R → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
N1420E1420Abolished formation of an inflammasome filament together with PYCARD/ASC.
N → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1422E1422Abolished formation of an inflammasome filament together with PYCARD/ASC.
R → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1427D1427Abolished formation of an inflammasome filament together with PYCARD/ASC.
R → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
R1427E1427Impaired ability to induce programmed cell death.
R → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1428E1428Does not affect formation of an inflammasome filament together with PYCARD/ASC.
K → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Q1434R1434Does not affect formation of an inflammasome filament together with PYCARD/ASC.
Q → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
D1437R1437Abolished formation of an inflammasome filament together with PYCARD/ASC.
D → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Y1445A1445Abolished inflammasome filament formation. Impaired ability to induce programmed cell death, but retains CAPS1 processing.
Y → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
K1449D1449Does not affect formation of an inflammasome filament together with PYCARD/ASC.
K → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1450R1450Abolished formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
T1451R1451Abolished formation of an inflammasome filament together with PYCARD/ASC.
T → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1454D1454Abolished formation of an inflammasome filament together with PYCARD/ASC.
H → D
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
H1454E1454Abolished formation of an inflammasome filament together with PYCARD/ASC.
H → E
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
M1457A1457Does not affect ability to induce programmed cell death.
M → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1458R1458Abolished formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
W1460A1460Does not affect ability to induce programmed cell death.
W → A
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
E1461R1461Does not affect formation of an inflammasome filament together with PYCARD/ASC.
E → R
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
05

PTM/Processing

NACHT, LRR and PYD domains-containing protein 1

Autocatalytically cleaved [22, 10, 50]. Autocatalytic cleavage in FIIND region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding [22, 10, 50]. Both N- and C-terminal parts remain associated non-covalently [22, 10, 50]

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22087307"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        }
      ],
      "value": "Autocatalytically cleaved (PubMed:22087307, PubMed:22665479, PubMed:33093214). Autocatalytic cleavage in FIIND region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding (PubMed:22087307, PubMed:22665479, PubMed:33093214). Both N- and C-terminal parts remain associated non-covalently (PubMed:22087307, PubMed:22665479, PubMed:33093214)"
    }
  ],
  "commentType": "PTM",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1"
}
NACHT, LRR and PYD domains-containing protein 1, N-terminus

Ubiquitinated by the cullin:ZER1/ZYG11B complex in response to pathogen-associated signals, leading to its degradation by the proteasome and subsequent release of the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        }
      ],
      "value": "Ubiquitinated by the cullin:ZER1/ZYG11B complex in response to pathogen-associated signals, leading to its degradation by the proteasome and subsequent release of the cleaved C-terminal part of the protein (NACHT, LRR and PYD domains-containing protein 1, C-terminus), which polymerizes and forms the NLRP1 inflammasome"
    }
  ],
  "commentType": "PTM",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}

Phosphorylated by MAP3K20 isoform ZAKalpha, MAPK11 and MAPK14 in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35857590"
        }
      ],
      "value": "Phosphorylated by MAP3K20 isoform ZAKalpha, MAPK11 and MAPK14 in response to UV-B irradiation and ribosome collisions, promoting activation of the NLRP1 inflammasome and pyroptosis"
    }
  ],
  "commentType": "PTM"
}

(Microbial infection) Cleaved between Gln-130 and Gly-131 by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16) [50, 35]. This cleavage triggers N-glycine-mediated proteasomal degradation of the autoinhibitory NLRP1 N-terminal fragment via the cullin:ZER1/ZYG11B complex which liberates the activating C-terminal fragment and activates NLRP1 inflammasome [50]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33410748"
        }
      ],
      "value": "(Microbial infection) Cleaved between Gln-130 and Gly-131 by the Protease 3C from various human enteroviruses and rhinoviruses (EV68, EV71, Coxsackievirus B3, HRV-14 and HRV-16) (PubMed:33093214, PubMed:33410748). This cleavage triggers N-glycine-mediated proteasomal degradation of the autoinhibitory NLRP1 N-terminal fragment via the cullin:ZER1/ZYG11B complex which liberates the activating C-terminal fragment and activates NLRP1 inflammasome (PubMed:33093214)"
    }
  ],
  "commentType": "PTM"
}

(Microbial infection) Cleaved between Gln-333 and Gly-334 by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2 [36]. This cleavage liberates the activating C-terminal fragment and activates NLRP1 inflammasome, leading to downstream activation of GSDME and lung epithelial cell death [36]

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35594856"
        }
      ],
      "value": "(Microbial infection) Cleaved between Gln-333 and Gly-334 by the 3C-like proteinase nsp5 from human coronavirus SARS-CoV-2 (PubMed:35594856). This cleavage liberates the activating C-terminal fragment and activates NLRP1 inflammasome, leading to downstream activation of GSDME and lung epithelial cell death (PubMed:35594856)"
    }
  ],
  "commentType": "PTM"
}

Processed chains & precursor regions 3

Scroll across the table for evidence and actions.

3 recorded rows

FeaturePositionDescriptionEvidenceInspect
ChainPRO_00000967101–1473NACHT, LRR and PYD domains-containing protein 1
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
ChainPRO_00004528511–1212NACHT, LRR and PYD domains-containing protein 1, N-terminus
Curator inference 1 publication
Evidence & references
No verified residues in this structure
ChainPRO_00004528521213–1473NACHT, LRR and PYD domains-containing protein 1, C-terminus
Curator inference 1 publication
Evidence & references
No verified residues in this structure

Modifications 16

Scroll across the table for evidence and actions.

16 recorded rows

FeaturePositionDescriptionEvidenceInspect
Modified residue93Phosphoserine; by MAPK11 and MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue99Phosphoserine; by MAPK11 and MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue101Phosphoserine; by MAPK11 and MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue107Phosphoserine; by MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue112Phosphothreonine; by MAPK11, MAPK14 and MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue113Phosphoserine; by MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue114Phosphothreonine; by MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue129Phosphothreonine; by MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue132Phosphoserine; by MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue163Phosphoserine; by MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue168Phosphoserine; by MAPK11 and MAPk14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue170Phosphoserine; by MAPK11 and MAPK14
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue173Phosphoserine; by MAPK11
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue178Phosphothreonine; by MAPK11
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue179Phosphoserine; by MAPK11 and MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Modified residue180Phosphothreonine; by MAPK11 and MAP3K20
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
06

Expression

Widely expressed [4, 17]. Abundantly expressed in primary immune cells (isoform 1 and isoform 2), including in neutrophils, monocytes/macrophages, dendritic cells (mostly Langerhans cells), and B- and T-lymphocytes (at protein level) [13, 17]. Strongly expressed in epithelial cells lining the glandular epithelium, such as that of the gastrointestinal tract (stomach, small intestine, colon), the respiratory tract (trachea and bronchi), and the endometrial and endocervical glands, gallbladder, prostate, and breast (at protein level).

In testis, expressed in spermatogonia and primary spermatocytes, but not in Sertoli cells (at protein level). In the brain, expressed in neurons, in particular in pyramidal ones and in oligodendrocytes, but not detected in microglia (at protein level) [17]. Expressed in adult and fetal ocular tissues, including in adult and 24-week old fetal choroid, sclera, cornea, and optic nerve, as well as in adult retina and fetal retina/retinal pigment epithelium [46].

Highly expressed in the skin throughout the epidermis and in dermal fibroblasts, in both glabrous skin and plantar skin. It is detected in keratinocytes, but not in melanocytes. Expressed in epidermal appendages such as hair follicles [47]

Experimental evidence 5 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11113115"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15285719"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17164409"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "23349227"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "27662089"
        }
      ],
      "value": "Widely expressed (PubMed:11113115, PubMed:17164409). Abundantly expressed in primary immune cells (isoform 1 and isoform 2), including in neutrophils, monocytes/macrophages, dendritic cells (mostly Langerhans cells), and B- and T-lymphocytes (at protein level) (PubMed:15285719, PubMed:17164409). Strongly expressed in epithelial cells lining the glandular epithelium, such as that of the gastrointestinal tract (stomach, small intestine, colon), the respiratory tract (trachea and bronchi), and the endometrial and endocervical glands, gallbladder, prostate, and breast (at protein level). In testis, expressed in spermatogonia and primary spermatocytes, but not in Sertoli cells (at protein level). In the brain, expressed in neurons, in particular in pyramidal ones and in oligodendrocytes, but not detected in microglia (at protein level) (PubMed:17164409). Expressed in adult and fetal ocular tissues, including in adult and 24-week old fetal choroid, sclera, cornea, and optic nerve, as well as in adult retina and fetal retina/retinal pigment epithelium (PubMed:23349227). Highly expressed in the skin throughout the epidermis and in dermal fibroblasts, in both glabrous skin and plantar skin. It is detected in keratinocytes, but not in melanocytes. Expressed in epidermal appendages such as hair follicles (PubMed:27662089)"
    }
  ],
  "commentType": "TISSUE SPECIFICITY"
}

Developmental stage

Associated with differentiation in stratified epithelia of the skin, esophagus, intestine, and cervix, as well as in the prostate gland. Undetectable in undifferentiated basal cells, but expressed in differentiated luminal secretory cells [4]. Expressed in differentiated macrophages and granulocytes, but not their precursors (at protein level) [4, 13].

In testis, also associated with cell differentiation, with conflicting results. Expressed in spermatogonia and primary spermatocytes, but not in cells from later differentiation stages, including secondary spermatocytes, spermatids, and spermatozoa (at protein level) [17]. Not detected in spermatocytes, nor spermatids, and strongly expressed in spermatozoa (at protein level) [4]

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "11113115"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "15285719"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17164409"
        }
      ],
      "value": "Associated with differentiation in stratified epithelia of the skin, esophagus, intestine, and cervix, as well as in the prostate gland. Undetectable in undifferentiated basal cells, but expressed in differentiated luminal secretory cells (PubMed:11113115). Expressed in differentiated macrophages and granulocytes, but not their precursors (at protein level) (PubMed:11113115, PubMed:15285719). In testis, also associated with cell differentiation, with conflicting results. Expressed in spermatogonia and primary spermatocytes, but not in cells from later differentiation stages, including secondary spermatocytes, spermatids, and spermatozoa (at protein level) (PubMed:17164409). Not detected in spermatocytes, nor spermatids, and strongly expressed in spermatozoa (at protein level) (PubMed:11113115)"
    }
  ],
  "commentType": "DEVELOPMENTAL STAGE"
}

Induction

Up-regulated by ATF4 during endoplasmic reticulum (ER) stress response [28]. Up-regulated in arterial endothelial cells exposed to plasma from patients with peripheral arterial disease, but not to plasma from healthy controls [25]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "24439873"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "26086088"
        }
      ],
      "value": "Up-regulated by ATF4 during endoplasmic reticulum (ER) stress response (PubMed:26086088). Up-regulated in arterial endothelial cells exposed to plasma from patients with peripheral arterial disease, but not to plasma from healthy controls (PubMed:24439873)"
    }
  ],
  "commentType": "INDUCTION"
}
07

Interaction

Documented interaction partners

UniProt’s filtered IntAct records. Experiment counts describe reported experiments, not binding strength or independent publications. Separate products remain separate rows.

5 records
Partner / productSpeciesExperimentsEvidence & actions
BCL2P10415With Q9C000Homo sapiens13
IntAct evidence

Pair evidence in IntAct ↗

Source product: Q9C000. Partner: P10415. Reported experiment count: 13.

Open protein ↗
BCL2L1Q07817With Q9C000Homo sapiens9
IntAct evidence

Pair evidence in IntAct ↗

Source product: Q9C000. Partner: Q07817. Reported experiment count: 9.

Open protein ↗
BCL2L1Q07817-1With Q9C000Homo sapiens2
IntAct evidence

Pair evidence in IntAct ↗

Source product: Q9C000. Partner: Q07817-1. Reported experiment count: 2.

Open protein ↗
CASP1P29466With Q9C000Homo sapiens3
IntAct evidence

Pair evidence in IntAct ↗

Source product: Q9C000. Partner: P29466. Reported experiment count: 3.

Open protein ↗
PYCARDQ9ULZ3With Q9C000Homo sapiens5
IntAct evidence

Pair evidence in IntAct ↗

Source product: Q9C000. Partner: Q9ULZ3. Reported experiment count: 5.

Open protein ↗

Complex membership & assembly descriptions

Co-membership does not by itself prove direct binding between every pair.

NLRP1 inflammasome CPX-4082 Complex Portal

Homo sapiens; 9606 ·

Evidence: inferred by curator

  • NLRP1 · Q9C000 ·
  • CASP1 · P29466 ·
  • PYCARD · Q9ULZ3 ·

A pro-inflammatory thiol protease complex that is activated in response to pathogen infections and toxins (e.g. Anthrax lethal toxin). Primarily acts in monocytes and macrophages. Activating platform for Caspase-1 (CPX-952) through proximity-induced self-cleavage in an ATP-dependent reaction. Activated Caspase-1 cleaves interleukins 1beta (IL1B, P01584) and IL18 (Q14116) releasing the mature cytokines which are involved in a variety of inflammatory processes and is also involved in pyroptosis of macrophages, a special case of cell death, associated with infection by intracellular pathogens where it cleaves GSDMD (P57764). Belongs to the family of Inflammasomes that includes NLRP3 inflammasome (CPX-4141), NLRC4 inflammasome (CPX-4144), AIM2 inflammasome (CPX-4142) and Pyrin inflammasome (CPX-4143). Single-nucleotide polymorphisms in the NLRP1 gene are associated with vitiligo.

Source & references ↗

UniProt subunit description

Interacts (via LRR repeats) with BCL2 and BCL2L1 (via the loop between motifs BH4 and BH3); these interactions reduce NLRP1 inflammasome-induced CASP1 activation and IL1B release, possibly by impairing NLRP1 interaction with PYCARD [15]. Interacts with NOD2; this interaction is enhanced in the presence of muramyl dipeptide (MDP) and increases IL1B release [19]. Interacts with EIF2AK2/PKR; this interaction requires EIF2AK2 activity, is accompanied by EIF2AK2 autophosphorylation and promotes inflammasome assembly in response to danger-associated signals [23].

Interacts with MEFV; this interaction targets NLRP1 to degradation by autophagy, hence preventing excessive IL1B- and IL18-mediated inflammation [16, 26]. Binds (via LRR domain) to dsDNA and dsRNA [33]. Interacts with DPP9; leading to inhibit activation of the inflammasome [29, 31, 42].

DPP9 acts via formation of a ternary complex, composed of a DPP9 homodimer, one full-length NLRP1 protein, and one cleaved C-terminus of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) [42]. Interacts with DPP8; leading to inhibit activation of the inflammasome, probably via formation of a ternary complex with DPP8 [31]

Experimental evidence 9 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17418785"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17431422"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "18511561"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22801494"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "26347139"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "30291141"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "31525884"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33731932"
        }
      ],
      "value": "Interacts (via LRR repeats) with BCL2 and BCL2L1 (via the loop between motifs BH4 and BH3); these interactions reduce NLRP1 inflammasome-induced CASP1 activation and IL1B release, possibly by impairing NLRP1 interaction with PYCARD (PubMed:17418785). Interacts with NOD2; this interaction is enhanced in the presence of muramyl dipeptide (MDP) and increases IL1B release (PubMed:18511561). Interacts with EIF2AK2/PKR; this interaction requires EIF2AK2 activity, is accompanied by EIF2AK2 autophosphorylation and promotes inflammasome assembly in response to danger-associated signals (PubMed:22801494). Interacts with MEFV; this interaction targets NLRP1 to degradation by autophagy, hence preventing excessive IL1B- and IL18-mediated inflammation (PubMed:17431422, PubMed:26347139). Binds (via LRR domain) to dsDNA and dsRNA (PubMed:33243852). Interacts with DPP9; leading to inhibit activation of the inflammasome (PubMed:30291141, PubMed:31525884, PubMed:33731932). DPP9 acts via formation of a ternary complex, composed of a DPP9 homodimer, one full-length NLRP1 protein, and one cleaved C-terminus of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) (PubMed:33731932). Interacts with DPP8; leading to inhibit activation of the inflammasome, probably via formation of a ternary complex with DPP8 (PubMed:31525884)"
    }
  ],
  "commentType": "SUBUNIT"
}
NACHT, LRR and PYD domains-containing protein 1, N-terminus

Interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in absence of pathogens and other damage-associated signals

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        }
      ],
      "value": "Interacts with the C-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, C-terminus) in absence of pathogens and other damage-associated signals"
    }
  ],
  "commentType": "SUBUNIT",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}
NACHT, LRR and PYD domains-containing protein 1, C-terminus

Interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus) in absence of pathogens and other damage-associated signals [50]. Homomultimer; forms the NLRP1 inflammasome polymeric complex, a filament composed of homopolymers of this form in response to pathogens and other damage-associated signals [43, 44]. The NLRP1 inflammasome polymeric complex associates with PYCARD/ASC [12, 18, 15, 10].

Interacts (via CARD domain) with PYCARD/ASC (via CARD domain); leading to pro-caspase-1 (proCASP1) recruitment [12, 15, 10]. Pro-caspase-1 (proCASP1) filament formation increases local enzyme concentration, resulting in trans-autocleavage and activation [12, 18, 10]. Active CASP1 then processes IL1B and IL18 precursors, leading to the release of mature cytokines in the extracellular milieu and inflammatory response [12, 18, 10]

Experimental evidence 7 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12191486"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17349957"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17418785"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33093214"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33420028"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33420033"
        }
      ],
      "value": "Interacts with the N-terminal part of NLRP1 (NACHT, LRR and PYD domains-containing protein 1, N-terminus) in absence of pathogens and other damage-associated signals (PubMed:33093214). Homomultimer; forms the NLRP1 inflammasome polymeric complex, a filament composed of homopolymers of this form in response to pathogens and other damage-associated signals (PubMed:33420028, PubMed:33420033). The NLRP1 inflammasome polymeric complex associates with PYCARD/ASC (PubMed:12191486, PubMed:17349957, PubMed:17418785, PubMed:22665479). Interacts (via CARD domain) with PYCARD/ASC (via CARD domain); leading to pro-caspase-1 (proCASP1) recruitment (PubMed:12191486, PubMed:17418785, PubMed:22665479). Pro-caspase-1 (proCASP1) filament formation increases local enzyme concentration, resulting in trans-autocleavage and activation (PubMed:12191486, PubMed:17349957, PubMed:22665479). Active CASP1 then processes IL1B and IL18 precursors, leading to the release of mature cytokines in the extracellular milieu and inflammatory response (PubMed:12191486, PubMed:17349957, PubMed:22665479)"
    }
  ],
  "commentType": "SUBUNIT",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}

(Microbial infection) Interacts with vaccinia virus protein F1 [24]

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "16439990"
        }
      ],
      "value": "(Microbial infection) Interacts with vaccinia virus protein F1 (PubMed:16439990)"
    }
  ],
  "commentType": "SUBUNIT"
}
NACHT, LRR and PYD domains-containing protein 1, N-terminus

(Microbial infection) Interacts with human herpes virus 8/HHV-8 proteins ORF45; relieving autoinhibition of the NLRP1 inflammasome

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35618833"
        }
      ],
      "value": "(Microbial infection) Interacts with human herpes virus 8/HHV-8 proteins ORF45; relieving autoinhibition of the NLRP1 inflammasome"
    }
  ],
  "commentType": "SUBUNIT",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, N-terminus"
}

Other association resources

Resource links only; their association networks and counts are not added to the partner table.

08

Structure

6X6C · Cryo-EM structure of NLRP1-DPP9-VbP complex

ELECTRON MICROSCOPY · 2.9 Å

Recorded components

ComponentSpeciesChainsProtein identities
Dipeptidyl peptidase 9protein · Entity 1Homo sapiensA, BQ86TI2
NACHT, LRR and PYD domains-containing protein 1protein · Entity 2Homo sapiensC, DQ9C000
[(2~{R})-1-[(2~{R})-2-azanyl-3-methyl-butanoyl]pyrrolidin-2-yl]boronic acidligand · Entity 3E, FNo verified protein mapping

Biological assemblies

Assembly 1 · author_defined_assembly
Recorded chains: A, B, C, D, E, F

Assembly membership does not establish direct binding. Observed residue coverage is checked against the loaded coordinates; it is not inferred from construct metadata.

Publication

DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation.

17/03/2021 · Read publication ↗

Detailed validation, construct lengths and deposition dates are not included in this published record. See the source record for those details.

PDB source record ↗

Structure references are from the dated source record. Opening another structure follows your existing Atlas account permissions.

Available structures 13

Scroll across the table for evidence and actions.

13 recorded rows

RecordEvidence typeMethodResolutionOpen
6X6CexperimentalEM2.90 AOpen in Atlas ↗
6X6AexperimentalEM3.60 AOpen in Atlas ↗
7WGEexperimentalEM3.40 AOpen in Atlas ↗
4IM6experimentalX-ray1.65 AOpen in Atlas ↗
8ZGDexperimentalX-ray2.05 AOpen in Atlas ↗
5Y3SexperimentalX-ray2.45 AOpen in Atlas ↗
4IFPexperimentalX-ray1.99 AOpen in Atlas ↗
3KATexperimentalX-ray3.10 AOpen in Atlas ↗
6XKKexperimentalEM3.60 AOpen in Atlas ↗
6K7VexperimentalEM3.70 AOpen in Atlas ↗
1PN5experimentalNMR-Open in Atlas ↗
9BJ9experimentalEM4.20 AOpen in Atlas ↗
AF-Q9C000-F1predictedAlphaFoldNot applicableOpen in Atlas ↗
09

Family & Domains

The CARD domain, rather than the pyrin domain, is involved in the interaction with PYCARD, CASP1 and CASP5

Experimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12191486"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17349957"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        }
      ],
      "value": "The CARD domain, rather than the pyrin domain, is involved in the interaction with PYCARD, CASP1 and CASP5"
    }
  ],
  "commentType": "DOMAIN"
}

The ZAKalpha motifs are recognized and phosphorylated by isoform ZAKalpha of MAP3K20

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "35857590"
        }
      ],
      "value": "The ZAKalpha motifs are recognized and phosphorylated by isoform ZAKalpha of MAP3K20"
    }
  ],
  "commentType": "DOMAIN"
}

The leucine-rich repeat (LRR) domain may be involved in autoinhibition in the absence of activating signal, possibly through intramolecular interaction with the NACHT domain. Serves as the predominant binding domain for dsRNA and dsDNA [33]

By similarityExperimental evidence 3 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q9EPB4"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "12191486"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "17349957"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        }
      ],
      "value": "The leucine-rich repeat (LRR) domain may be involved in autoinhibition in the absence of activating signal, possibly through intramolecular interaction with the NACHT domain. Serves as the predominant binding domain for dsRNA and dsDNA (PubMed:33243852)"
    }
  ],
  "commentType": "DOMAIN"
}

The FIIND (domain with function to find) region is involved in homomerization, but not in CASP1-binding (By similarity). Autocatalytic cleavage in this region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding [22, 10]. Both N- and C-terminal fragments remain associated [22, 10]

By similarityExperimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000250",
          "source": "UniProtKB",
          "id": "Q2LKW6"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22087307"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "22665479"
        }
      ],
      "value": "The FIIND (domain with function to find) region is involved in homomerization, but not in CASP1-binding (By similarity). Autocatalytic cleavage in this region occurs constitutively, prior to activation signals, and is required for inflammasome activity (IL1B release), possibly by facilitating CASP1 binding (PubMed:22087307, PubMed:22665479). Both N- and C-terminal fragments remain associated (PubMed:22087307, PubMed:22665479)"
    }
  ],
  "commentType": "DOMAIN"
}

The pyrin domain mediates an autoinhibitory function, potentially acting as a threshold modulator, which allows NLRP1 to discriminate long from short dsRNA. Inhibits ATPase activity of the NATCH domain

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        }
      ],
      "value": "The pyrin domain mediates an autoinhibitory function, potentially acting as a threshold modulator, which allows NLRP1 to discriminate long from short dsRNA. Inhibits ATPase activity of the NATCH domain"
    }
  ],
  "commentType": "DOMAIN"
}
NACHT, LRR and PYD domains-containing protein 1, C-terminus

The C-terminal part of NLRP1 oligomerizes to form the core of the NLRP1 inflammasome filament: in the filament, the CARD domains form a central helical filaments that are promoted by oligomerized, but flexibly linked, UPA regions surrounding the filaments [43, 44]. The UPA region reduces the threshold needed for filament formation and signaling [43, 44]. Must recruit the adapter PYCARD/ASC to facilitate CASP1 interaction and polymerization [44]

Experimental evidence 2 publications
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33420028"
        },
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33420033"
        }
      ],
      "value": "The C-terminal part of NLRP1 oligomerizes to form the core of the NLRP1 inflammasome filament: in the filament, the CARD domains form a central helical filaments that are promoted by oligomerized, but flexibly linked, UPA regions surrounding the filaments (PubMed:33420028, PubMed:33420033). The UPA region reduces the threshold needed for filament formation and signaling (PubMed:33420028, PubMed:33420033). Must recruit the adapter PYCARD/ASC to facilitate CASP1 interaction and polymerization (PubMed:33420033)"
    }
  ],
  "commentType": "DOMAIN",
  "molecule": "NACHT, LRR and PYD domains-containing protein 1, C-terminus"
}

Upon dsRNA-binding via its LRR domain, NACHT domain gains ATPase activity which is inhibited by the pyrin domain

Experimental evidence 1 publication
Evidence & references
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000269",
          "source": "PubMed",
          "id": "33243852"
        }
      ],
      "value": "Upon dsRNA-binding via its LRR domain, NACHT domain gains ATPase activity which is inhibited by the pyrin domain"
    }
  ],
  "commentType": "DOMAIN"
}

Belongs to the NLRP family

Curator inference
Evidence & references
  • ECO:0000305
Complete source annotation
{
  "texts": [
    {
      "evidences": [
        {
          "evidenceCode": "ECO:0000305"
        }
      ],
      "value": "Belongs to the NLRP family"
    }
  ],
  "commentType": "SIMILARITY"
}

Domain architecture

Canonical sequence11473 aa

Canonical coordinates. Overlapping marks share a lane; individual records and evidence are in the tables below. Gaps in coverage are not selectable in 3D. Use the track links and tables for keyboard inspection.

Atlas domains, motifs & repeats 18

Scroll across the table for evidence and actions.

18 recorded rows

AnnotationPositionSource & interpretationInspect
DAPIN domainIPR0040201–92INTERPROdomain

The DAPIN (Domain in Apoptosis and INterferon response) domain is an 80-100- residue domain which is found in the N terminus of diverse vertebrate and vertebrate-specific viral proteins involved in apoptosis, cancer, inflammation, and immune response. The DAPIN domain can be found alone or in association with other domains like CARD, LRR, SPRY, Caspase or Zinc finger B-box.

Full source description

The DAPIN (Domain in Apoptosis and INterferon response) domain is an 80-100- residue domain which is found in the N terminus of diverse vertebrate and vertebrate-specific viral proteins involved in apoptosis, cancer, inflammation, and immune response. The DAPIN domain can be found alone or in association with other domains like CARD, LRR, SPRY, Caspase or Zinc finger B-box. It has been proposed that the DAPIN domain might have an adaptor function, coupling apoptosis and immune disorders. It has been shown that the DAPIN domain is a protein-protein interaction domain capable of binding to other DAPIN domains. Secondary structure predictions have identified the DAPIN domain as mostly α-helical and it has been suggested that it could belong to the DEATH- domain-fold superfamily, which includes the CARD, the DEATH domain (DD) and the DEATH effector domain (DED). The DAPIN domain has also been called pyrin domain, pyrin N-terminal homology domain (PYD) or PAAD (after the protein families pyrin, AIM, ASC death-domain- like).

Source entry ↗
No verified residues in this structure
NACHT nucleoside triphosphataseIPR007111328–637INTERPROdomain

The NACHT domain is a 300 to 400 residue predicted nucleoside triphosphatase (NTPase) domain, which is found in animal, fungal and bacterial proteins. The NACHT domain has been named after NAIP, CIITA, HET-E and TP1.

Full source description

The NACHT domain is a 300 to 400 residue predicted nucleoside triphosphatase (NTPase) domain, which is found in animal, fungal and bacterial proteins. The NACHT domain has been named after NAIP, CIITA, HET-E and TP1. It is found in association with other domains, such as the CARD domain ([interpro:IPR001315]), the DAPIN domain ([interpro:IPR004020]), the HEAT repeat ([interpro:IPR004155]), the WD repeat ([interpro:IPR001680]), the leucine-rich repeat (LRR) or the BIR repeat ([interpro:IPR001370]). The NACHT domain consists of seven distinct conserved motifs, including the ATP/GTPase specific P-loop, the Mg(2+)-binding site (Walker A and B motifs, respectively) and five more specific motifs. The unique features of the NACHT domain include the prevalence of 'tiny' residues (glycine, alanine or serine) directly C-terminal of the Mg(2+)-coordinating aspartate in the Walker B motif, in place of a second acidic residue prevalent in other NTPases. A second acidic residue is typically found in the NACHT-containing proteins two positions downstream. Furthermore, the distal motif VII contains a conserved pattern of polar, aromatic and hydrophobic residues that is not seen in any other NTPase family.

Source entry ↗
No verified residues in this structure
NOD1/2, winged helix domainIPR041075567–615INTERPROdomain

This winged helix domain is found in the NOD1, NOD2 and related proteins that play a role in immune response. In NLRP3, this domain is important for ATB binding.

Source entry ↗
No verified residues in this structure
NACHT, LRR and PYD domains-containing protein, helical domain HD2IPR041267623–733INTERPROdomain

This entry represents the second of two helical domains (HD2) found in the NLRC proteins, the NOD2 protein and NACHT, LRR and PYD domains-containing proteins.

Source entry ↗
No verified residues in this structure
Leucine rich repeat, ribonuclease inhibitor typeSM00368807–834SMARTdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
LRR RegionCLUSTER_LRR_809_973809–973ALPHASUITEdomain

6 LRR repeats grouped into a tandem region.

No verified residues in this structure
Leucine-rich repeatIPR001611809–830INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
No verified residues in this structure
Leucine rich repeat, ribonuclease inhibitor typeSM00368836–863SMARTdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
LRR 2UNI_REPEAT_838_858838–858UNIPROTrepeat

LRR 2

Source entry ↗
No verified residues in this structure
Leucine rich repeat, ribonuclease inhibitor typeSM00368864–891SMARTdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
Leucine-rich repeatIPR001611864–886INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
No verified residues in this structure
Leucine rich repeat, ribonuclease inhibitor typeSM00368893–920SMARTdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
LRR 4UNI_REPEAT_895_915895–915UNIPROTrepeat

LRR 4

Source entry ↗
No verified residues in this structure
Leucine rich repeat, ribonuclease inhibitor typeSM00368921–948SMARTdomain

No description available for this entry.

Source entry ↗
No verified residues in this structure
Leucine-rich repeatIPR001611921–943INTERPROrepeat

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response.

Full source description

Leucine-rich repeats (LRR) consist of 2-45 motifs of 20-30 amino acids in length that generally folds into an arc or horseshoe shape. LRRs occur in proteins ranging from viruses to eukaryotes, and appear to provide a structural framework for the formation of protein-protein interactions.Proteins containing LRRs include tyrosine kinase receptors, cell-adhesion molecules, virulence factors, and extracellular matrix-binding glycoproteins, and are involved in a variety of biological processes, including signal transduction, cell adhesion, DNA repair, recombination, transcription, RNA processing, disease resistance, apoptosis, and the immune response. Sequence analyses of LRR proteins suggested the existence of several different subfamilies of LRRs. The significance of this classification is that repeats from different subfamilies never occur simultaneously and have most probably evolved independently. It is, however, now clear that all major classes of LRR have curved horseshoe structures with a parallel β sheet on the concave side and mostly helical elements on the convex side. At least six families of LRR proteins, characterised by different lengths and consensus sequences of the repeats, have been identified. Eleven-residue segments of the LRRs (LxxLxLxxN/CxL), corresponding to the β-strand and adjacent loop regions, are conserved in LRR proteins, whereas the remaining parts of the repeats (herein termed variable) may be very different. Despite the differences, each of the variable parts contains two half-turns at both ends and a "linear" segment (as the chain follows a linear path overall), usually formed by a helix, in the middle. The concave face and the adjacent loops are the most common protein interaction surfaces on LRR proteins. 3D structure of some LRR proteins-ligand complexes show that the concave surface of LRR domain is ideal for interaction with α-helix, thus supporting earlier conclusions that the elongated and curved LRR structure provides an outstanding framework for achieving diverse protein-protein interactions. Molecular modeling suggests that the conserved pattern LxxLxL, which is shorter than the previously proposed LxxLxLxxN/CxL is sufficient to impart the characteristic horseshoe curvature to proteins with 20-to 30-residue repeats.

Source entry ↗
No verified residues in this structure
LRR 6UNI_REPEAT_950_973950–973UNIPROTrepeat

LRR 6

Source entry ↗
No verified residues in this structure
FIIND domainIPR0253071079–1364INTERPROdomain

This entry contains the whole FIIND domain [prosite:PS51830] composed by the ZU5 sub-domain [pfam:PF13553] and the UPA sub-domain [pfam:PF23679]. The so-called function-to-find (FIIND) domain was initially identified in two proteins: NLRP1 (also known as NALP1, CARD7, NAC, DEFCAP) and CARD8 (also known as TUCAN, Cardinal).

Full source description

This entry contains the whole FIIND domain [prosite:PS51830] composed by the ZU5 sub-domain [pfam:PF13553] and the UPA sub-domain [pfam:PF23679]. The so-called function-to-find (FIIND) domain was initially identified in two proteins: NLRP1 (also known as NALP1, CARD7, NAC, DEFCAP) and CARD8 (also known as TUCAN, Cardinal). NLRP1 is a member of the Nod-like receptor (NLR) protein superfamily and is involved in apoptosis and inflammation; to date, it remains the only NLR protein known to possess a FIIND domain. The domain is likewise present in CARD8, where, as in NLRP1, it is followed by a C-terminal CARD domain. Both proteins are reported to form an "inflammasome", a macromolecular complex capable of processing caspase-1 and activating pro-IL1β. The FIIND domain comprises two subdomains: ZU5 (found in the tight-junction protein ZO-1 and the netrin receptor UNC5) and UPA (conserved in UNC5, the death-domain-containing protein PIDD, and proteins of the ankyrin family). Notably, the FIIND domain is found in only a small subset of the animal kingdom, including primates, rodents (mouse, rat), carnivores (e.g., dog), and a few other species such as horses. Early studies describing NLRP1 did not initially recognise FIIND as a distinct domain, mistakenly identifying it as part of the adjacent leucine-rich repeat (LRR) domain. The discovery of CARD8 later revealed that its N-terminal region shared significant sequence identity with an uncharacterised region in NLRP1. Before receiving its current designation, the FIIND domain was referred to as the NALP1-associated domain (NAD).

Source entry ↗
No verified residues in this structure
CARD domainIPR0013151380–1463INTERPROdomain

The caspase recruitment domain (CARD domain) is a homotypic protein interaction module composed of a bundle of six α-helices. CARD is related in sequence and structure to the death domain (DD, see [interpro:IPR000488]) and the death effector domain (DED, see [interpro:IPR001875]), which work in similar pathways and show similar interaction properties.

Full source description

The caspase recruitment domain (CARD domain) is a homotypic protein interaction module composed of a bundle of six α-helices. CARD is related in sequence and structure to the death domain (DD, see [interpro:IPR000488]) and the death effector domain (DED, see [interpro:IPR001875]), which work in similar pathways and show similar interaction properties. The CARD domain typically associates with other CARD-containing proteins, forming either dimers or trimers. CARD domains can be found in isolation, or in combination with other domains. Domains associated with CARD include: NACHT ([interpro:IPR007111]) (in Nal1 and Bir1), NB-ARC ([interpro:IPR002182]) (in Apaf-1), pyrin/dapin domains ([interpro:IPR004020]) (in Nal1), leucine-rich repeats ([interpro:IPR001611]) (in Nal1), WD repeats ([interpro:IPR001680]) (in Apaf1), Src homology domains ([interpro:IPR001452]), PDZ ([interpro:IPR001478]), RING, kinase and DD domains. CARD-containing proteins are involved in apoptosis through their regulation of caspases that contain CARDs in their N-terminal pro-domains, including human caspases 1, 2, 9, 11 and 12. CARD-containing proteins are also involved in inflammation through their regulation of NF-kappaB. The mechanisms by which CARDs activate caspases and NF-kappaB involve the assembly of multi-protein complexes, which can facilitate dimerisation or serve as scaffolds on which proteases and kinases are assembled and activated.

Source entry ↗
No verified residues in this structure

UniProt domains, repeats & motifs 12

Scroll across the table for evidence and actions.

12 recorded rows

FeaturePositionDescriptionEvidenceInspect
Domain1–92Pyrin
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00061
No verified residues in this structure
Domain328–637NACHT
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00136
No verified residues in this structure
Repeat809–830LRR 1
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat838–858LRR 2
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat866–887LRR 3
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat895–915LRR 4
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat923–944LRR 5
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Repeat950–973LRR 6
Evidence & references

No separate evidence record is supplied for this statement.

No verified residues in this structure
Domain1079–1364FIIND
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU01174
No verified residues in this structure
Domain1374–1463CARD
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00046
No verified residues in this structure
Motif111–117ZAKalpha motif 1
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Motif177–183ZAKalpha motif 2
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure

Functional sites 4

Scroll across the table for evidence and actions.

4 recorded rows

FeaturePositionDescriptionEvidenceInspect
Binding site334–341Binding site
Sequence analysis
Evidence & references
  • ECO:0000255 PROSITE-ProRule:PRU00136
No verified residues in this structure
Site130–131(Microbial infection) Cleavage; by human rhinovirus 14 (HRV-14) Protease 3C
Experimental evidence 2 publications
Evidence & references
No verified residues in this structure
Site333–334(Microbial infection) Cleavage; by coronavirus SARS-CoV-2 proteinase nsp5
Experimental evidence 1 publication
Evidence & references
No verified residues in this structure
Site1212–1213Cleavage; by autolysis
Sequence analysisExperimental evidence 1 publication
Evidence & references
No verified residues in this structure

Sequence regions 7

Scroll across the table for evidence and actions.

7 recorded rows

FeaturePositionDescriptionEvidenceInspect
Region90–113Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region160–254Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region991–1017Disordered
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Region1079–1212ZU5
Published statement 1 publication
Evidence & references
No verified residues in this structure
Region1213–1364UPA
Published statement 1 publication
Evidence & references
No verified residues in this structure
Compositional bias170–182Polar residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
Compositional bias218–231Basic and acidic residues
Evidence & references
  • ECO:0000256 SAM:MobiDB-lite
No verified residues in this structure
10

Sequence & Isoforms

Sequence & isoforms

UniProt’s canonical sequence is its selected representative. It is not necessarily the dominant isoform in every tissue.

UniProt’s canonical sequence · Q9C000-11473 aa165,866 Da · source sequence mass

The mass describes this unmodified source sequence, not every mature or modified product.

MAGGAWGRLACYLEFLKKEELKEFQLLLANKAHSRSSSGETPAQPEKTSGMEVASYLVAQYGEQRAWDLALHTWEQMGLRSLCAQAQEGAGHSPSFPYSPSEPHLGSPSQPTSTAVLMPWIHELPAGCTQGSERRVLRQLPDTSGRRWREISASLLYQALPSSPDHESPSQESPNAPTSTAVLGSWGSPPQPSLAPREQEAPGTQWPLDETSGIYYTEIREREREKSEKGRPPWAAVVGTPPQAHTSLQPHHHPWEPSVRESLCSTWPWKNEDFNQKFTQLLLLQRPHPRSQDPLVKRSWPDYVEENRGHLIEIRDLFGPGLDTQEPRIVILQGAAGIGKSTLARQVKEAWGRGQLYGDRFQHVFYFSCRELAQSKVVSLAELIGKDGTATPAPIRQILSRPERLLFILDGVDEPGWVLQEPSSELCLHWSQPQPADALLGSLLGKTILPEASFLITARTTALQNLIPSLEQARWVEVLGFSESSRKEYFYRYFTDERQAIRAFRLVKSNKELWALCLVPWVSWLACTCLMQQMKRKEKLTLTSKTTTTLCLHYLAQALQAQPLGPQLRDLCSLAAEGIWQKKTLFSPDDLRKHGLDGAIISTFLKMGILQEHPIPLSYSFIHLCFQEFFAAMSYVLEDEKGRGKHSNCIIDLEKTLEAYGIHGLFGASTTRFLLGLLSDEGEREMENIFHCRLSQGRNLMQWVPSLQLLLQPHSLESLHCLYETRNKTFLTQVMAHFEEMGMCVETDMELLVCTFCIKFSRHVKKLQLIEGRQHRSTWSPTMVVLFRWVPVTDAYWQILFSVLKVTRNLKELDLSGNSLSHSAVKSLCKTLRRPRCLLETLRLAGCGLTAEDCKDLAFGLRANQTLTELDLSFNVLTDAGAKHLCQRLRQPSCKLQRLQLVSCGLTSDCCQDLASVLSASPSLKELDLQQNNLDDVGVRLLCEGLRHPACKLIRLGLDQTTLSDEMRQELRALEQEKPQLLIFSRRKPSVMTPTEGLDTGEMSNSTSSLKRQRLGSERAASHVAQANLKLLDVSKIFPIAEIAEESSPEVVPVELLCVPSPASQGDLHTKPLGTDDDFWGPTGPVATEVVDKEKNLYRVHFPVAGSYRWPNTGLCFVMREAVTVEIEFCVWDQFLGEINPQHSWMVAGPLLDIKAEPGAVEAVHLPHFVALQGGHVDTSLFQMAHFKEEGMLLEKPARVELHHIVLENPSFSPLGVLLKMIHNALRFIPVTSVVLLYHRVHPEEVTFHLYLIPSDCSIRKAIDDLEMKFQFVRIHKPPPLTPLYMGCRYTVSGSGSGMLEILPKELELCYRSPGEDQLFSEFYVGHLGSGIRLQVKDKKDETLVWEALVKPGDLMPATTLIPPARIAVPSPLDAPQLLHFVDQYREQLIARVTSVEVVLDKLHGQVLSQEQYERVLAENTRPSQMRKLFSLSQSWDRKCKDGLYQALKETHPHLIMELWEKGSKKGLLPLSS

Source isoform notes & selection

Alternative splicing

Complete source annotation
{
  "commentType": "ALTERNATIVE PRODUCTS",
  "events": [
    "Alternative splicing"
  ],
  "isoforms": [
    {
      "name": {
        "value": "1"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC beta"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "DEFCAP-L"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15285719"
            }
          ],
          "value": "NALP1-L"
        }
      ],
      "isoformIds": [
        "Q9C000-1"
      ],
      "isoformSequenceStatus": "Displayed"
    },
    {
      "name": {
        "value": "2"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC alpha"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "DEFCAP-S"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15285719"
            }
          ],
          "value": "NALP1-S"
        },
        {
          "value": "NLRP1deltaEx14"
        }
      ],
      "isoformIds": [
        "Q9C000-2"
      ],
      "sequenceIds": [
        "VSP_004327"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "3"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC gamma"
        }
      ],
      "isoformIds": [
        "Q9C000-3"
      ],
      "sequenceIds": [
        "VSP_004326",
        "VSP_004327"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "4"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC delta"
        }
      ],
      "isoformIds": [
        "Q9C000-4"
      ],
      "sequenceIds": [
        "VSP_004326"
      ],
      "isoformSequenceStatus": "Described"
    },
    {
      "name": {
        "value": "5"
      },
      "isoformIds": [
        "Q9C000-5"
      ],
      "sequenceIds": [
        "VSP_053803",
        "VSP_053804",
        "VSP_053805"
      ],
      "isoformSequenceStatus": "Described"
    }
  ]
}
  • Q9C000-1 · 1 · Displayed · NAC beta, DEFCAP-L, NALP1-L
    Complete source annotation
    {
      "name": {
        "value": "1"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC beta"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "DEFCAP-L"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15285719"
            }
          ],
          "value": "NALP1-L"
        }
      ],
      "isoformIds": [
        "Q9C000-1"
      ],
      "isoformSequenceStatus": "Displayed"
    }
  • Q9C000-2 · 2 · Described · NAC alpha, DEFCAP-S, NALP1-S, NLRP1deltaEx14 · VSP_004327
    Complete source annotation
    {
      "name": {
        "value": "2"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC alpha"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11076957"
            }
          ],
          "value": "DEFCAP-S"
        },
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "15285719"
            }
          ],
          "value": "NALP1-S"
        },
        {
          "value": "NLRP1deltaEx14"
        }
      ],
      "isoformIds": [
        "Q9C000-2"
      ],
      "sequenceIds": [
        "VSP_004327"
      ],
      "isoformSequenceStatus": "Described"
    }
  • Q9C000-3 · 3 · Described · NAC gamma · VSP_004326, VSP_004327
    Complete source annotation
    {
      "name": {
        "value": "3"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC gamma"
        }
      ],
      "isoformIds": [
        "Q9C000-3"
      ],
      "sequenceIds": [
        "VSP_004326",
        "VSP_004327"
      ],
      "isoformSequenceStatus": "Described"
    }
  • Q9C000-4 · 4 · Described · NAC delta · VSP_004326
    Complete source annotation
    {
      "name": {
        "value": "4"
      },
      "synonyms": [
        {
          "evidences": [
            {
              "evidenceCode": "ECO:0000303",
              "source": "PubMed",
              "id": "11113115"
            }
          ],
          "value": "NAC delta"
        }
      ],
      "isoformIds": [
        "Q9C000-4"
      ],
      "sequenceIds": [
        "VSP_004326"
      ],
      "isoformSequenceStatus": "Described"
    }
  • Q9C000-5 · 5 · Described · VSP_053803, VSP_053804, VSP_053805
    Complete source annotation
    {
      "name": {
        "value": "5"
      },
      "isoformIds": [
        "Q9C000-5"
      ],
      "sequenceIds": [
        "VSP_053803",
        "VSP_053804",
        "VSP_053805"
      ],
      "isoformSequenceStatus": "Described"
    }

Isoform sequence differences 5

Scroll across the table for evidence and actions.

5 recorded rows

FeaturePositionDescriptionEvidenceInspect
Alternative sequenceVSP_004326958–987in isoform 3 and isoform 4
Published statement 1 publication
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0538031044in isoform 5
A → AGKSH
Published statement 2 publications
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0043271262–1305in isoform 2 and isoform 3
Published statement 5 publications
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0538041354–1371in isoform 5
DLMPATTLIPPARIAVPS → RNTSQPWNLRCNRDARRY
Published statement 2 publications
Evidence & references
No verified residues in this structure
Alternative sequenceVSP_0538051372–1473in isoform 5
Published statement 2 publications
Evidence & references
No verified residues in this structure

Sequence conflicts & cautions 3

Scroll across the table for evidence and actions.

3 recorded rows

FeaturePositionDescriptionEvidenceInspect
Sequence conflict287in Ref. 7; AAH51787
P → S
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict782in Ref. 1; AAG15254
T → S
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Sequence conflict995in Ref. 1; AAG15254
T → I
Curator inference
Evidence & references
  • ECO:0000305
No verified residues in this structure
Erroneous initiation

Source sequence: BAA76770.2

Extended N-terminus.

Curator inference
Evidence & references
  • ECO:0000305
Miscellaneous discrepancy

Source sequence: BAB15469.1

Probable cloning artifact.

Curator inference
Evidence & references
  • ECO:0000305
Miscellaneous discrepancy

Source sequence: BAB15470.1

Probable cloning artifact.

Curator inference
Evidence & references
  • ECO:0000305

Recorded secondary structure 112

Scroll across the table for evidence and actions.

112 recorded rows

FeaturePositionDescriptionEvidenceInspect
Helix9–15Helix
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Helix18–31Helix
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Helix50–60Helix
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Helix63–77Helix
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Helix80–85Helix
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Beta strand88–91Beta strand
Evidence & references
  • ECO:0007829 PDB:1PN5
No verified residues in this structure
Beta strand286–288Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix300–306Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix314–316Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand322–324Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand328–333Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn340–342Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix343–353Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn358–360Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand362–366Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix369–374Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix380–387Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand389–391Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix395–399Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix402–404Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand405–408Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand412–415Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand422–425Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix436–444Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand447–451Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand453–457Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand459–461Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn464–466Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand474–478Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix483–491Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix497–509Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix511–516Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix520–535Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix547–558Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand559–561Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix566–580Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix588–593Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix598–607Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand609–611Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand614–617Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand619–622Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix624–639Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix656–659Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn660–662Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn665–667Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix669–676Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix682–689Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix698–701Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix703–709Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix716–723Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Turn728–733Turn
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix748–759Helix
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand760–763Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand766–770Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Beta strand783–787Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix796–804Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand807–809Beta strand
Evidence & references
  • ECO:0007829 PDB:5Y3S
No verified residues in this structure
Beta strand812–814Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix822–833Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand840–843Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix851–862Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand869–871Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix878–889Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand898–900Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix908–910Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix911–920Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand926–928Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand931–933Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Helix935–946Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand955–957Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand961–963Beta strand
Evidence & references
  • ECO:0007829 PDB:7WGE
No verified residues in this structure
Helix965–977Helix
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand982–984Beta strand
Evidence & references
  • ECO:0007829 PDB:4IM6
No verified residues in this structure
Beta strand986–988Beta strand
Evidence & references
  • ECO:0007829 PDB:8ZGD
No verified residues in this structure
Beta strand1089–1092Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Turn1093–1096Turn
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1097–1102Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1104–1106Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Turn1111–1113Turn
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1116–1118Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1123–1129Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Helix1132–1138Helix
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Turn1142–1144Turn
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1145–1147Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1152–1156Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1163–1166Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1174–1176Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1179–1181Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1184–1188Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1191–1195Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1198–1200Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1218–1220Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1223–1225Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1234–1236Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1241–1253Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Helix1257–1269Helix
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1289–1294Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1305–1308Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1314–1316Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1320–1327Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1333–1338Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Turn1339–1341Turn
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Beta strand1344–1349Beta strand
Evidence & references
  • ECO:0007829 PDB:6X6C
No verified residues in this structure
Helix1381–1384Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1386–1392Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1396–1403Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Turn1405–1407Turn
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1410–1417Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Beta strand1419–1421Beta strand
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1422–1433Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1438–1451Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
Helix1453–1462Helix
Evidence & references
  • ECO:0007829 PDB:4IFP
No verified residues in this structure
12

Homologs

OMA orthologs

Evolutionary relationships assigned by OMA, kept separate from sequence clusters. “1:1” describes an orthology relationship, not percentage identity.

Recorded preview of up to 12 orthologs; not an exhaustive list. Entries without a verified UniProt mapping open their OMA record.

13

Sources & References

Scientific descriptions and evidence come from the named sources. Atlas assembles the presentation and verifies residue mappings; it does not independently curate these claims.

Source dates & provenance

Recorded 2026-11-10. Source dates and identifiers are retained below.

Publications in this UniProt entry

1 · The PYRIN domain: a novel motif found in apoptosis and inflammation proteins.

2000 · Cell Death Differ.

PubMed 11270363 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2); VARIANTS HIS-155; SER-246; MET-878; VAL-1119; VAL-1184; LEU-1241 AND CYS-1366

Bertin J., DiStefano P.S.

2 · The pyrin domain: a possible member of the death domain-fold family implicated in apoptosis and inflammation.

2001 · Curr. Biol.

PubMed 11250163 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2)

Martinon F., Hofmann K., Tschopp J.

3 · Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins.

2001 · J. Biol. Chem.

PubMed 11076957 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2); MUTAGENESIS OF LYS-340

Hlaing T., Guo R.-F., Dilley K.A., Loussia J.M., Morrish T.A., Shi M.M., Vincenz C., Ward P.A.

4 · A novel enhancer of the Apaf1 apoptosome involved in cytochrome c-dependent caspase activation and apoptosis.

2001 · J. Biol. Chem.

PubMed 11113115 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2; 3 AND 4); FUNCTION; TISSUE SPECIFICITY; DEVELOPMENTAL STAGE

Chu Z.-L., Pio F., Xie Z., Welsh K., Krajewska M., Krajewski S., Godzik A., Reed J.C.

All source publications (50)
5 · Prediction of the coding sequences of unidentified human genes. XIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.

1999 · DNA Res.

PubMed 10231032 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2)

Nagase T., Ishikawa K., Suyama M., Kikuno R., Hirosawa M., Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.

6 · DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage.

2006 · Nature

PubMed 16625196 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]

Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J., DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D., Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A., Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.

7 · The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).

2004 · Genome Res.

PubMed 15489334 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5)

8 · The full-ORF clone resource of the German cDNA consortium.

2007 · BMC Genomics

PubMed 17974005 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 282-1473 (ISOFORM 1); VARIANT VAL-1184

Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U., Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A., Wiemann S., Schupp I.

9 · Complete sequencing and characterization of 21,243 full-length human cDNAs.

2004 · Nat. Genet.

PubMed 14702039 ↗
Scope & authors

NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 508-1473

Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.

10 · Autolytic proteolysis within the function to find domain (FIIND) is required for NLRP1 inflammasome activity.

2012 · J. Biol. Chem.

PubMed 22665479 ↗
Scope & authors

PROTEIN SEQUENCE OF 1213-1224; FUNCTION; INTERACTION WITH PYCARD; INVOLVEMENT IN INFLAMMASOME COMPLEX; AUTOCATALYTIC CLEAVAGE; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANTS VAL-1119 AND VAL-1184; MUTAGENESIS OF HIS-1168; HIS-1186; SER-1211; PHE-1212; SER-1213; PRO-1214 AND HIS-1249

Finger J.N., Lich J.D., Dare L.C., Cook M.N., Brown K.K., Duraiswami C., Bertin J.J., Bertin J., Gough P.J.

· Reference

2012 · J. Biol. Chem.

Scope & authors

ERRATUM OF PUBMED:22665479

Finger J.N., Lich J.D., Dare L.C., Cook M.N., Brown K.K., Duraiswami C., Bertin J.J., Bertin J., Gough P.J.

12 · The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.

2002 · Mol. Cell

PubMed 12191486 ↗
Scope & authors

FUNCTION; INTERACTION WITH CASP1; CASP5 AND PYCARD; AUTOINHIBITION; IDENTIFICATION IN INFLAMMASOME COMPLEX

Martinon F., Burns K., Tschopp J.

13 · NALP1 is a transcriptional target for cAMP-response-element-binding protein (CREB) in myeloid leukaemia cells.

2004 · Biochem. J.

PubMed 15285719 ↗
Scope & authors

TISSUE SPECIFICITY; DEVELOPMENTAL STAGE

Sanz C., Calasanz M.J., Andreu E., Richard C., Prosper F., Fernandez-Luna J.L.

14 · Expression of NALP1 in cerebellar granule neurons stimulates apoptosis.

2004 · Cell. Signal.

PubMed 15212762 ↗
Scope & authors

FUNCTION; MUTAGENESIS OF 339-GLY-LYS-340

Liu F., Lo C.F., Ning X., Kajkowski E.M., Jin M., Chiriac C., Gonzales C., Naureckiene S., Lock Y.-W., Pong K., Zaleska M.M., Jacobsen J.S., Silverman S., Ozenberger B.A.

15 · Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1.

2007 · Cell

PubMed 17418785 ↗
Scope & authors

FUNCTION; INTERACTION WITH BCL2; BCL2L1; CASP5 AND PYCARD; SUBCELLULAR LOCATION; ACTIVATION BY MDP

Bruey J.M., Bruey-Sedano N., Luciano F., Zhai D., Balpai R., Xu C., Kress C.L., Bailly-Maitre B., Li X., Osterman A., Matsuzawa S., Terskikh A.V., Faustin B., Reed J.C.

16 · The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1beta processing.

2007 · Cell Death Differ.

PubMed 17431422 ↗
Scope & authors

INTERACTION WITH MEFV

Papin S., Cuenin S., Agostini L., Martinon F., Werner S., Beer H.D., Grutter C., Grutter M., Tschopp J.

17 · Inflammasome components NALP 1 and 3 Show distinct but separate expression profiles in human tissues suggesting a site-specific role in the inflammatory response.

2007 · J. Histochem. Cytochem.

PubMed 17164409 ↗
Scope & authors

SUBCELLULAR LOCATION; TISSUE SPECIFICITY; DEVELOPMENTAL STAGE

Kummer J.A., Broekhuizen R., Everett H., Agostini L., Kuijk L., Martinon F., van Bruggen R., Tschopp J.

18 · Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation.

2007 · Mol. Cell

PubMed 17349957 ↗
Scope & authors

FUNCTION; INTERACTION WITH CASP1; AUTOINHIBITION; HOMOMERIZATION; ACTIVATION BY MDP

Faustin B., Lartigue L., Bruey J.-M., Luciano F., Sergienko E., Bailly-Maitre B., Volkmann N., Hanein D., Rouiller I., Reed J.C.

19 · A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide.

2008 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 18511561 ↗
Scope & authors

FUNCTION; INTERACTION WITH NOD2; ACTIVATION BY MDP

Hsu L.C., Ali S.R., McGillivray S., Tseng P.H., Mariathasan S., Humke E.W., Eckmann L., Powell J.J., Nizet V., Dixit V.M., Karin M.

20 · The NLRP1 and CARD8 inflammasomes.

2020 · Immunol. Rev.

PubMed 32558991 ↗
Scope & authors

REVIEW

Taabazuing C.Y., Griswold A.R., Bachovchin D.A.

21 · Expression of Nlrp1b inflammasome components in human fibroblasts confers susceptibility to anthrax lethal toxin.

2009 · Infect. Immun.

PubMed 19651869 ↗
Scope & authors

LACK OF ACTIVATION BY ANTHRAX LETHAL TOXIN; ACTIVITY REGULATION

Liao K.C., Mogridge J.

22 · CARD8 and NLRP1 undergo autoproteolytic processing through a ZU5-like domain.

2011 · PLoS ONE

PubMed 22087307 ↗
Scope & authors

FUNCTION; AUTOCATALYTIC CLEAVAGE; MUTAGENESIS OF SER-1213

D'Osualdo A., Weichenberger C.X., Wagner R.N., Godzik A., Wooley J., Reed J.C.

23 · Novel role of PKR in inflammasome activation and HMGB1 release.

2012 · Nature

PubMed 22801494 ↗
Scope & authors

FUNCTION; INTERACTION WITH EIF2AK2

Lu B., Nakamura T., Inouye K., Li J., Tang Y., Lundbaeck P., Valdes-Ferrer S.I., Olofsson P.S., Kalb T., Roth J., Zou Y., Erlandsson-Harris H., Yang H., Ting J.P., Wang H., Andersson U., Antoine D.J., Chavan S.S., Hotamisligil G.S., Tracey K.J.

24 · Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis.

2006 · Cell Death Differ.

PubMed 16439990 ↗
Scope & authors

INTERACTION WITH VACCINIA VIRUS PROTEIN F1

Postigo A., Cross J.R., Downward J., Way M.

25 · NLRP1 inflammasome, and not NLRP3, is the key in the shift to proinflammatory state on endothelial cells in peripheral arterial disease.

2014 · Int. J. Cardiol.

PubMed 24439873 ↗
Scope & authors

INDUCTION

Bleda S., de Haro J., Varela C., Esparza L., Ferruelo A., Acin F.

26 · TRIM-mediated precision autophagy targets cytoplasmic regulators of innate immunity.

2015 · J. Cell Biol.

PubMed 26347139 ↗
Scope & authors

INTERACTION WITH MEFV

Kimura T., Jain A., Choi S.W., Mandell M.A., Schroder K., Johansen T., Deretic V.

27 · Caspase-1 activity is required for UVB-induced apoptosis of human keratinocytes.

2015 · J. Invest. Dermatol.

PubMed 25562666 ↗
Scope & authors

FUNCTION

Sollberger G., Strittmatter G.E., Grossi S., Garstkiewicz M., Auf dem Keller U., French L.E., Beer H.D.

28 · Transcription factor ATF4 induces NLRP1 inflammasome expression during endoplasmic reticulum stress.

2015 · PLoS ONE

PubMed 26086088 ↗
Scope & authors

INDUCTION BY ATF4

D'Osualdo A., Anania V.G., Yu K., Lill J.R., Kaufman R.J., Matsuzawa S., Reed J.C.

29 · Human DPP9 represses NLRP1 inflammasome and protects against autoinflammatory diseases via both peptidase activity and FIIND domain binding.

2018 · J. Biol. Chem.

PubMed 30291141 ↗
Scope & authors

FUNCTION; ACTIVITY REGULATION; SUBCELLULAR LOCATION; CHARACTERIZATION OF VARIANT AIADK ARG-1214

Zhong F.L., Robinson K., Teo D.E.T., Tan K.Y., Lim C., Harapas C.R., Yu C.H., Xie W.H., Sobota R.M., Au V.B., Hopkins R., D'Osualdo A., Reed J.C., Connolly J.E., Masters S.L., Reversade B.

30 · Genome Editing of Human Primary Keratinocytes by CRISPR/Cas9 Reveals an Essential Role of the NLRP1 Inflammasome in UVB Sensing.

2018 · J. Invest. Dermatol.

PubMed 30096351 ↗
Scope & authors

FUNCTION

Fenini G., Grossi S., Contassot E., Biedermann T., Reichmann E., French L.E., Beer H.D.

31 · DPP9's enzymatic activity and not its binding to CARD8 inhibits inflammasome activation.

2019 · ACS Chem. Biol.

PubMed 31525884 ↗
Scope & authors

INTERACTION WITH DPP8 AND DPP9; ACTIVITY REGULATION; MUTAGENESIS OF SER-1213

Griswold A.R., Ball D.P., Bhattacharjee A., Chui A.J., Rao S.D., Taabazuing C.Y., Bachovchin D.A.

32 · Caspase-1 interdomain linker cleavage is required for pyroptosis.

2020 · Life Sci. Alliance

PubMed 32051255 ↗
Scope & authors

FUNCTION; PROTEOLYTIC CLEAVAGE; MUTAGENESIS OF SER-1213

Ball D.P., Taabazuing C.Y., Griswold A.R., Orth E.L., Rao S.D., Kotliar I.B., Vostal L.E., Johnson D.C., Bachovchin D.A.

33 · Human NLRP1 is a sensor for double-stranded RNA.

2020 · Science

PubMed 33243852 ↗
Scope & authors

FUNCTION; ACTIVITY REGULATION; DOMAIN; MUTAGENESIS OF SER-1213; DNA-BINDING; RNA-BINDING; CATALYTIC ACTIVITY

Bauernfried S., Scherr M.J., Pichlmair A., Duderstadt K.E., Hornung V.

34 · Gasdermin E permits interleukin-1 beta release in distinct sublytic and pyroptotic phases.

2021 · Cell Rep.

PubMed 33852854 ↗
Scope & authors

FUNCTION

Zhou B., Abbott D.W.

35 · Diverse viral proteases activate the NLRP1 inflammasome.

2021 · Elife

PubMed 33410748 ↗
Scope & authors

FUNCTION; ACTIVITY REGULATION; PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); MUTAGENESIS OF GLY-130

Tsu B.V., Beierschmitt C., Ryan A.P., Agarwal R., Mitchell P.S., Daugherty M.D.

36 · Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells.

2022 · Mol. Cell

PubMed 35594856 ↗
Scope & authors

FUNCTION; ACTIVITY REGULATION (MICROBIAL INFECTION); PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); MUTAGENESIS OF GLN-333

Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K., Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R., Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y., Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O., Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S., Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.

37 · Structural and biochemical mechanisms of NLRP1 inhibition by DPP9.

2021 · Nature

PubMed 33731929 ↗
Scope & authors

FUNCTION; ACTIVITY REGULATION; MUTAGENESIS OF PRO-1278 AND LEU-1281

Huang M., Zhang X., Toh G.A., Gong Q., Wang J., Han Z., Wu B., Zhong F., Chai J.

38 · KSHV-encoded ORF45 activates human NLRP1 inflammasome.

2022 · Nat. Immunol.

PubMed 35618833 ↗
Scope & authors

SUBCELLULAR LOCATION (MICROBIAL INFECTION); INTERACTION WITH HERPES VIRUS 8/HHV-8 PROTEINS ORF45

Yang X., Zhou J., Liu C., Qu Y., Wang W., Xiao M.Z.X., Zhu F., Liu Z., Liang Q.

39 · ZAKalpha-driven ribotoxic stress response activates the human NLRP1 inflammasome.

2022 · Science

PubMed 35857590 ↗
Scope & authors

FUNCTION; PHOSPHORYLATION AT SER-93; SER-99; SER-101; SER-107; THR-112; SER-113; THR-114; THR-129; SER-132; SER-163; SER-168; SER-170; SER-173; THR-178; SER-179 AND THR-180; MUTAGENESIS OF 178-THR--THR-180

Robinson K.S., Toh G.A., Rozario P., Chua R., Bauernfried S., Sun Z., Firdaus M.J., Bayat S., Nadkarni R., Poh Z.S., Tham K.C., Harapas C.R., Lim C.K., Chu W., Tay C.W.S., Tan K.Y., Zhao T., Bonnard C., Sobota R., Connolly J.E., Common J., Masters S.L., Chen K.W., Ho L., Wu B., Hornung V., Zhong F.L.

40 · NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain.

2003 · Structure

PubMed 14527388 ↗
Scope & authors

STRUCTURE BY NMR OF 1-93

Hiller S., Kohl A., Fiorito F., Herrmann T., Wider G., Tschopp J., Gruetter M.G., Wuethrich K.

· Northeast structural genomics consortium target HR3486E.

OCT-2009 ·

Scope & authors

X-RAY CRYSTALLOGRAPHY

42 · DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation.

2021 · Nature

PubMed 33731932 ↗
Scope & authors

STRUCTURE BY ELECTRON MICROSCOPY IN COMPLEX WITH DPP9; FUNCTION; ACTIVITY REGULATION; INTERACTION WITH DPP9; MUTAGENESIS OF 1193-LEU-LEU-1194; SER-1213; HIS-1276; LYS-1277 AND GLU-1322; CHARACTERIZATION OF VARIANT AIADK ARG-1214

Hollingsworth L.R., Sharif H., Griswold A.R., Fontana P., Mintseris J., Dagbay K.B., Paulo J.A., Gygi S.P., Bachovchin D.A., Wu H.

43 · Structural basis for distinct inflammasome complex assembly by human NLRP1 and CARD8.

2021 · Nat. Commun.

PubMed 33420028 ↗
Scope & authors

STRUCTURE BY ELECTRON MICROSCOPY; SUBCELLULAR LOCATION; SUBUNIT; DOMAIN; MUTAGENESIS OF ARG-1240; 1260-ARG-LYS-1261; 1278-PRO-PRO-1279; PHE-1320; ASP-1383; ARG-1386; GLU-1387; GLN-1388; ARG-1392; SER-1395; GLU-1397; LYS-1402; HIS-1404; GLN-1406; GLN-1410; GLU-1411; TYR-1413; GLU-1414; ARG-1415; ASN-1420; ARG-1422; ARG-1427; LYS-1428; GLN-1434; ASP-1437; LYS-1449; GLU-1450; THR-1451; HIS-1454; GLU-1458 AND GLU-1461

Gong Q., Robinson K., Xu C., Huynh P.T., Chong K.H.C., Tan E.Y.J., Zhang J., Boo Z.Z., Teo D.E.T., Lay K., Zhang Y., Lim J.S.Y., Goh W.I., Wright G., Zhong F.L., Reversade B., Wu B.

44 · Mechanism of filament formation in UPA-promoted CARD8 and NLRP1 inflammasomes.

2021 · Nat. Commun.

PubMed 33420033 ↗
Scope & authors

STRUCTURE BY ELECTRON MICROSCOPY; SUBCELLULAR LOCATION; SUBUNIT; DOMAIN; MUTAGENESIS OF ARG-1392; GLU-1397; ASP-1401; GLU-1411; GLU-1414; ARG-1427; TYR-1445; MET-1457; TRP-1460 AND GLU-1461

Robert Hollingsworth L., David L., Li Y., Griswold A.R., Ruan J., Sharif H., Fontana P., Orth-He E.L., Fu T.M., Bachovchin D.A., Wu H.

45 · NALP1 in vitiligo-associated multiple autoimmune disease.

2007 · N. Engl. J. Med.

PubMed 17377159 ↗
Scope & authors

INVOLVEMENT IN VAMAS1; VARIANT HIS-155

Jin Y., Mailloux C.M., Gowan K., Riccardi S.L., LaBerge G., Bennett D.C., Fain P.R., Spritz R.A.

46 · Whole exome sequencing identifies a mutation for a novel form of corneal intraepithelial dyskeratosis.

2013 · J. Med. Genet.

PubMed 23349227 ↗
Scope & authors

VARIANT MSPC THR-77; TISSUE SPECIFICITY

Soler V.J., Tran-Viet K.N., Galiacy S.D., Limviphuvadh V., Klemm T.P., St Germain E., Fournie P.R., Guillaud C., Maurer-Stroh S., Hawthorne F., Suarez C., Kantelip B., Afshari N.A., Creveaux I., Luo X., Meng W., Calvas P., Cassagne M., Arne J.L., Rozen S.G., Malecaze F., Young T.L.

47 · Germline NLRP1 mutations cause skin inflammatory and cancer susceptibility syndromes via inflammasome activation.

2016 · Cell

PubMed 27662089 ↗
Scope & authors

VARIANTS MSPC THR-54; VAL-66 AND 787-PHE--ARG-843 DEL; CHARACTERIZATION OF VARIANTS MSPC THR-54; VAL-66 AND 787-PHE--ARG-843 DEL; FUNCTION; TISSUE SPECIFICITY

Zhong F.L., Mamai O., Sborgi L., Boussofara L., Hopkins R., Robinson K., Szeverenyi I., Takeichi T., Balaji R., Lau A., Tye H., Roy K., Bonnard C., Ahl P.J., Jones L.A., Baker P., Lacina L., Otsuka A., Fournie P.R., Malecaze F., Lane E.B., Akiyama M., Kabashima K., Connolly J.E., Masters S.L., Soler V.J., Omar S.S., McGrath J.A., Nedelcu R., Gribaa M., Denguezli M., Saad A., Hiller S., Reversade B.

48 · A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (NLRP1-associated autoinflammation with arthritis and dyskeratosis).

2017 · Ann. Rheum. Dis.

PubMed 27965258 ↗
Scope & authors

INVOLVEMENT IN AIADK; VARIANTS AIADK TRP-726 AND ARG-1214

Grandemange S., Sanchez E., Louis-Plence P., Tran Mau-Them F., Bessis D., Coubes C., Frouin E., Seyger M., Girard M., Puechberty J., Costes V., Rodiere M., Carbasse A., Jeziorski E., Portales P., Sarrabay G., Mondain M., Jorgensen C., Apparailly F., Hoppenreijs E., Touitou I., Genevieve D.

49 · Homozygous NLRP1 gain-of-function mutation in siblings with a syndromic form of recurrent respiratory papillomatosis.

2019 · Proc. Natl. Acad. Sci. U.S.A.

PubMed 31484767 ↗
Scope & authors

INVOLVEMENT IN JRRP; FUNCTION; VARIANT JRRP ASN-755; CHARACTERIZATION OF VARIANT JRRP ASN-755

Drutman S.B., Haerynck F., Zhong F.L., Hum D., Hernandez N.J., Belkaya S., Rapaport F., de Jong S.J., Creytens D., Tavernier S.J., Bonte K., De Schepper S., van der Werff Ten Bosch J., Lorenzo-Diaz L., Wullaert A., Bossuyt X., Orth G., Bonagura V.R., Beziat V., Abel L., Jouanguy E., Reversade B., Casanova J.L.

50 · Enteroviral 3C protease activates the human NLRP1 inflammasome in airway epithelia.

2020 · Science

PubMed 33093214 ↗
Scope & authors

CHARACTERIZATION OF VARIANT MSPC THR-77; FUNCTION; ACTIVITY REGULATION; PROTEOLYTIC CLEAVAGE (MICROBIAL INFECTION); UBIQUITINATION; MUTAGENESIS OF GLN-76; GLN-85; GLN-87; GLN-110; GLN-130; GLN-139; GLN-158; GLN-171; GLN-191; GLN-199; GLN-205 AND PHE-1212

Robinson K.S., Teo D.E.T., Tan K.S., Toh G.A., Ong H.H., Lim C.K., Lay K., Au B.V., Lew T.S., Chu J.J.H., Chow V.T.K., Wang Y., Zhong F.L., Reversade B.

Annotation coverage audit

Every recorded UniProt comment and feature has a destination in this page. GO, Atlas annotations and interaction rows retain their separate source counts.

291 source comments and features accounted for.

View annotation inventory
Source recordTypeSection
FUNCTION:0FUNCTIONfunction
FUNCTION:1FUNCTIONfunction
FUNCTION:2FUNCTIONfunction
FUNCTION:3FUNCTIONfunction
FUNCTION:4FUNCTIONfunction
CATALYTIC ACTIVITY:0CATALYTIC ACTIVITYfunction
ACTIVITY REGULATION:0ACTIVITY REGULATIONfunction
ACTIVITY REGULATION:1ACTIVITY REGULATIONfunction
ACTIVITY REGULATION:2ACTIVITY REGULATIONfunction
SUBUNIT:0SUBUNITinteractions
SUBUNIT:1SUBUNITinteractions
SUBUNIT:2SUBUNITinteractions
SUBUNIT:3SUBUNITinteractions
SUBUNIT:4SUBUNITinteractions
INTERACTION:0INTERACTIONinteractions
SUBCELLULAR LOCATION:0SUBCELLULAR LOCATIONlocation
SUBCELLULAR LOCATION:1SUBCELLULAR LOCATIONlocation
SUBCELLULAR LOCATION:2SUBCELLULAR LOCATIONlocation
ALTERNATIVE PRODUCTS:0ALTERNATIVE PRODUCTSsequence
TISSUE SPECIFICITY:0TISSUE SPECIFICITYexpression
DEVELOPMENTAL STAGE:0DEVELOPMENTAL STAGEexpression
INDUCTION:0INDUCTIONexpression
DOMAIN:0DOMAINdomains
DOMAIN:1DOMAINdomains
DOMAIN:2DOMAINdomains
DOMAIN:3DOMAINdomains
DOMAIN:4DOMAINdomains
DOMAIN:5DOMAINdomains
DOMAIN:6DOMAINdomains
PTM:0PTMprocessing
PTM:1PTMprocessing
PTM:2PTMprocessing
PTM:3PTMprocessing
PTM:4PTMprocessing
DISEASE:0DISEASEdisease
DISEASE:1DISEASEdisease
DISEASE:2DISEASEdisease
DISEASE:3DISEASEdisease
MISCELLANEOUS:0MISCELLANEOUSfunction
SIMILARITY:0SIMILARITYdomains
SEQUENCE CAUTION:0SEQUENCE CAUTIONsequence
SEQUENCE CAUTION:1SEQUENCE CAUTIONsequence
SEQUENCE CAUTION:2SEQUENCE CAUTIONsequence
feature-0Chainprocessing
feature-1Chainprocessing
feature-2Chainprocessing
feature-3Domaindomains
feature-4Domaindomains
feature-5Repeatdomains
feature-6Repeatdomains
feature-7Repeatdomains
feature-8Repeatdomains
feature-9Repeatdomains
feature-10Repeatdomains
feature-11Domaindomains
feature-12Domaindomains
feature-13Regiondomains
feature-14Regiondomains
feature-15Regiondomains
feature-16Regiondomains
feature-17Regiondomains
feature-18Motifdomains
feature-19Motifdomains
feature-20Compositional biasdomains
feature-21Compositional biasdomains
feature-22Binding sitedomains
feature-23Sitedomains
feature-24Sitedomains
feature-25Sitedomains
feature-26Modified residueprocessing
feature-27Modified residueprocessing
feature-28Modified residueprocessing
feature-29Modified residueprocessing
feature-30Modified residueprocessing
feature-31Modified residueprocessing
feature-32Modified residueprocessing
feature-33Modified residueprocessing
feature-34Modified residueprocessing
feature-35Modified residueprocessing
feature-36Modified residueprocessing
feature-37Modified residueprocessing
feature-38Modified residueprocessing
feature-39Modified residueprocessing
feature-40Modified residueprocessing
feature-41Modified residueprocessing
feature-42Alternative sequencesequence
feature-43Alternative sequencesequence
feature-44Alternative sequencesequence
feature-45Alternative sequencesequence
feature-46Alternative sequencesequence
feature-47Natural variantdisease
feature-48Natural variantdisease
feature-49Natural variantdisease
feature-50Natural variantdisease
feature-51Natural variantdisease
feature-52Natural variantdisease
feature-53Natural variantdisease
feature-54Natural variantdisease
feature-55Natural variantdisease
feature-56Natural variantdisease
feature-57Natural variantdisease
feature-58Natural variantdisease
feature-59Natural variantdisease
feature-60Natural variantdisease
feature-61Natural variantdisease
feature-62Natural variantdisease
feature-63Natural variantdisease
feature-64Mutagenesisdisease
feature-65Mutagenesisdisease
feature-66Mutagenesisdisease
feature-67Mutagenesisdisease
feature-68Mutagenesisdisease
feature-69Mutagenesisdisease
feature-70Mutagenesisdisease
feature-71Mutagenesisdisease
feature-72Mutagenesisdisease
feature-73Mutagenesisdisease
feature-74Mutagenesisdisease
feature-75Mutagenesisdisease
feature-76Mutagenesisdisease
feature-77Mutagenesisdisease
feature-78Mutagenesisdisease
feature-79Mutagenesisdisease
feature-80Mutagenesisdisease
feature-81Mutagenesisdisease
feature-82Mutagenesisdisease
feature-83Mutagenesisdisease
feature-84Mutagenesisdisease
feature-85Mutagenesisdisease
feature-86Mutagenesisdisease
feature-87Mutagenesisdisease
feature-88Mutagenesisdisease
feature-89Mutagenesisdisease
feature-90Mutagenesisdisease
feature-91Mutagenesisdisease
feature-92Mutagenesisdisease
feature-93Mutagenesisdisease
feature-94Mutagenesisdisease
feature-95Mutagenesisdisease
feature-96Mutagenesisdisease
feature-97Mutagenesisdisease
feature-98Mutagenesisdisease
feature-99Mutagenesisdisease
feature-100Mutagenesisdisease
feature-101Mutagenesisdisease
feature-102Mutagenesisdisease
feature-103Mutagenesisdisease
feature-104Mutagenesisdisease
feature-105Mutagenesisdisease
feature-106Mutagenesisdisease
feature-107Mutagenesisdisease
feature-108Mutagenesisdisease
feature-109Mutagenesisdisease
feature-110Mutagenesisdisease
feature-111Mutagenesisdisease
feature-112Mutagenesisdisease
feature-113Mutagenesisdisease
feature-114Mutagenesisdisease
feature-115Mutagenesisdisease
feature-116Mutagenesisdisease
feature-117Mutagenesisdisease
feature-118Mutagenesisdisease
feature-119Mutagenesisdisease
feature-120Mutagenesisdisease
feature-121Mutagenesisdisease
feature-122Mutagenesisdisease
feature-123Mutagenesisdisease
feature-124Mutagenesisdisease
feature-125Mutagenesisdisease
feature-126Mutagenesisdisease
feature-127Mutagenesisdisease
feature-128Mutagenesisdisease
feature-129Mutagenesisdisease
feature-130Mutagenesisdisease
feature-131Mutagenesisdisease
feature-132Mutagenesisdisease
feature-133Sequence conflictsequence
feature-134Sequence conflictsequence
feature-135Sequence conflictsequence
feature-136Helixsequence
feature-137Helixsequence
feature-138Helixsequence
feature-139Helixsequence
feature-140Helixsequence
feature-141Beta strandsequence
feature-142Beta strandsequence
feature-143Helixsequence
feature-144Helixsequence
feature-145Beta strandsequence
feature-146Beta strandsequence
feature-147Turnsequence
feature-148Helixsequence
feature-149Turnsequence
feature-150Beta strandsequence
feature-151Helixsequence
feature-152Helixsequence
feature-153Beta strandsequence
feature-154Helixsequence
feature-155Helixsequence
feature-156Beta strandsequence
feature-157Beta strandsequence
feature-158Beta strandsequence
feature-159Helixsequence
feature-160Beta strandsequence
feature-161Beta strandsequence
feature-162Beta strandsequence
feature-163Turnsequence
feature-164Beta strandsequence
feature-165Helixsequence
feature-166Helixsequence
feature-167Helixsequence
feature-168Helixsequence
feature-169Helixsequence
feature-170Beta strandsequence
feature-171Helixsequence
feature-172Helixsequence
feature-173Helixsequence
feature-174Beta strandsequence
feature-175Beta strandsequence
feature-176Beta strandsequence
feature-177Helixsequence
feature-178Helixsequence
feature-179Turnsequence
feature-180Turnsequence
feature-181Helixsequence
feature-182Helixsequence
feature-183Helixsequence
feature-184Helixsequence
feature-185Helixsequence
feature-186Turnsequence
feature-187Helixsequence
feature-188Beta strandsequence
feature-189Beta strandsequence
feature-190Beta strandsequence
feature-191Helixsequence
feature-192Beta strandsequence
feature-193Beta strandsequence
feature-194Helixsequence
feature-195Beta strandsequence
feature-196Helixsequence
feature-197Beta strandsequence
feature-198Helixsequence
feature-199Beta strandsequence
feature-200Helixsequence
feature-201Helixsequence
feature-202Beta strandsequence
feature-203Beta strandsequence
feature-204Helixsequence
feature-205Beta strandsequence
feature-206Beta strandsequence
feature-207Helixsequence
feature-208Beta strandsequence
feature-209Beta strandsequence
feature-210Beta strandsequence
feature-211Turnsequence
feature-212Beta strandsequence
feature-213Beta strandsequence
feature-214Turnsequence
feature-215Beta strandsequence
feature-216Beta strandsequence
feature-217Helixsequence
feature-218Turnsequence
feature-219Beta strandsequence
feature-220Beta strandsequence
feature-221Beta strandsequence
feature-222Beta strandsequence
feature-223Beta strandsequence
feature-224Beta strandsequence
feature-225Beta strandsequence
feature-226Beta strandsequence
feature-227Beta strandsequence
feature-228Beta strandsequence
feature-229Beta strandsequence
feature-230Beta strandsequence
feature-231Helixsequence
feature-232Beta strandsequence
feature-233Beta strandsequence
feature-234Beta strandsequence
feature-235Beta strandsequence
feature-236Beta strandsequence
feature-237Turnsequence
feature-238Beta strandsequence
feature-239Helixsequence
feature-240Helixsequence
feature-241Helixsequence
feature-242Turnsequence
feature-243Helixsequence
feature-244Beta strandsequence
feature-245Helixsequence
feature-246Helixsequence
feature-247Helixsequence